Podcasts about Fyodor

Fyodor Dostoevsky was facing a firing squad. He quietly counted the last moments of his life. Dostoevsky, a believer in Jesus, is considered one of the greatest writers in all of literature. His monumental novel, The Brothers Karamazov, explored themes about God, life, and death. It was said of Dostoevsky, “He spoke about Christ ecstatically.” The rifles raised. “Ready! . . . Aim . . .” Jesus, alluding to His own execution, speaks to His disciples and to us of the eternal value of life and death when He said, “The hour has come” (John 12:23). The image is a seed (our life), which produces a great harvest through its own sacrifice (v. 24). Jesus tells us not to love this life too much, for it is those who are willing to sacrifice this present life who will find “eternal life” (v. 25). These are hard words—we cherish our life on earth. But Jesus is saying that being His disciple requires sacrifice. We’re counseled to hold life loosely, to embrace the joy of the life to come, and to find our hope in His words, “My Father will honor the one who serves me” (v. 26). Fyodor looked death in the face. But a letter from the Czar was delivered at the last second. A reprieve. Dostoevsky’s life was spared, yet this experience would infuse all of his later works. Indeed, the epigraph of The Brothers Karamazov is this verse, John 12:24: “Unless a kernel of wheat falls to the ground and dies, it remains only a single seed. But if it dies, it produces many seeds.”

In this episode, we sit down with Dr. Fyodor Tertitskiy, a longtime Seoul-based scholar of North Korean history and author of “Accidental Tyrant: The Life of Kim Il-sung,” a new biography of Kim Il Sung. Drawing on sources in Korean, Russian, Chinese and Japanese, Tertitskiy offers a fresh and deeply researched account of the man who founded one of the world's most enduring authoritarian regimes. We explore Kim's improbable rise from guerrilla fighter to head of state at just 33, how he consolidated power and created a system of hereditary rule, and why his legacy still looms large over North Korea today. Tertitskiy also discusses the mythmaking around Kim's persona, from teleportation to pine cone grenades, and examines the broader implications of his rule for global security and the study of dictatorship. Fyodor Tertitskiy has been residing in South Korea since 2011. He earned his PhD from Seoul National University in 2017 and is currently a lecturer at Korea University. His works can be found on his ResearchGate profile. He has recently published “Accidental Tyrant: The Life of Kim Il-sung,” a biography of Kim Il Sung.  About the podcast: The North Korea News Podcast is a weekly podcast hosted by Jacco Zwetsloot exclusively for NK News, covering all things DPRK — from news to extended interviews with leading experts and analysts in the field, along with insight from our very own journalists. NK News subscribers can listen to this and other exclusive episodes from their preferred podcast player by accessing the private podcast feed. For more detailed instructions, please see the step-by-step guide at nknews.org/private-feed.

"Do not be afraid of your fears, but cope with them—learn how to deal with them—because unless you do, you cannot live your life abundantly and fully." (Fyodor Raychynets)Evoking courage, resilience, and faith in the face of overwhelming uncertainty, Ukrainian pastor and theologian Fyodor Raychynets returns to For the Life of the World three years after the Russian invasion of Ukraine. In conversation with Evan Rosa, Fyodor shares his reflections on fear, freedom, and the emotional and spiritual challenges of living fully in a time of war. He discusses his response to recent global political developments, the struggle of holding onto hope, and the importance of confronting fear rather than suppressing it. Drawing from the Gospel of Mark's iteration of Jesus walking on water, his own personal grief and therapy, and the lived experience of war, Fyodor sees fear not as something to be avoided or gotten rid of, but as something to understand and face with courage."We are in a situation where we are scared to hope.""Do not be afraid of your fears, but cope with them—learn how to deal with them—because unless you do, you cannot live your life abundantly and fully.""If I want to say to someone, ‘I love you,' I say it. If I want to forgive, I forgive. If I want to do something meaningful, I do it now—because tomorrow is never guaranteed.""The enemy wants us to live in fear, to be paralyzed by it. But to live fully is to resist.""When Jesus scared his disciples on the water, he was bringing their fears to the surface—so that they could face them and find true freedom."Show NotesImage: “Walking on Water”, by Ivan Aivazovsky, Russia, 1888Episode SummaryUkrainian pastor and theologian Fyodor Raychynets reflects on faith, fear, and hope after three years of war.The role of fear in spiritual and personal transformation.A biblical perspective on confronting fear, drawn from the Gospel of Mark.Political and emotional reactions to recent global events impacting Ukraine.Living fully in the present as an act of resistance against fear and oppression.Faith, Fear, and FreedomFyodor Raychynets returns to discuss Ukraine's ongoing struggle and his evolving faith."Fear to hope"—the challenge of holding onto hope when the world is falling apart.Why fear should be faced rather than suppressed.The spiritual wisdom of encountering fear: “When Jesus scared his disciples, it was for their good.”The difference between being reckless, cowardly, or courageous—all of which share the common state of fear.The Ukrainian Perspective on Global PoliticsHow Ukraine perceives the shifting stance of U.S. foreign policy.The impact of Zelenskyy's visit to the Oval Office and international reactions.The challenge of fighting for democracy when global powers redefine the terms of war.The fear that democratic values are no longer upheld by those who once championed them.Biblical and Psychological Perspectives on FearMark's Gospel and the fear of encountering God in unexpected ways.Fyodor quotes Carl Jung: "Where our fears lie, that is where change is most needed."Facing fear as a practice of faith and emotional resilience.The importance of naming fears, localizing them, and even “inviting them in for tea.”How unprocessed fear can lead to paralysis or aggression.Living in the Present: The Antidote to FearWhy Fyodor refuses to postpone life until after the war."We don't know what tomorrow brings. So I live today, fully."A powerful response to fear: doing good, loving openly, and forgiving freely.The lesson of war: never get used to abnormal things.Holding onto humanity in the face of devastation.Linked Media ReferencesMark 6L: 45-52 Jesus Walks on WaterEpisode 110 of For the Life of the World A Voice from KyivEpisode 138 of For the Life of the World / Ukrainian Pastor Speaks Out: Resist Evil, Be Present, and Remember How Little You ControlUkraine War Updates - BBC NewsAbout Fyodor RaychynetsFyodor Raychynets is a theologian and pastor in Kyiv, Ukraine. He is Head of the Department of Theology at Ukrainian Evangelical Theological Seminary, where he teaches courses in Leadership and Biblical Studies, particularly the Gospel of Matthew. He studied with Miroslav Volf at Evangelical Theological Seminary in Osijek, Croatia.Follow him on Facebook here.Production NotesThis podcast featured Fyodor RaychinetsEdited and Produced by Evan RosaHosted by Evan RosaProduction Assistance by Macie Bridge, Alexa Rollow, Zoë Halaban, Kacie Barrett & Emily BrookfieldA Production of the Yale Center for Faith & Culture at Yale Divinity School https://faith.yale.edu/aboutSupport For the Life of the World podcast by giving to the Yale Center for Faith & Culture: https://faith.yale.edu/give

Russia, the US, Ukraine, Armenia, Georgian, and the New Global OrderConversations on Groong - February 16, 2025TopicsA New Détente?The Trump-Putin CallRussia's Strategic ChoicesRusso-Armenian RelationsRusso-Azerbaijani RelationsGeorgia's PragmatismGuestFyodor Lukyanov (Фёдор Алекса́ндрович Лукья́нов)HostsHovik ManucharyanAsbed BedrossianEpisode 414 | Recorded: Valentine's Day, February 14, 2025Video: https://youtu.be/55f4iBCIAGYSubscribe and follow us everywhere you are: linktr.ee/groong

Musicians and sound engineers Dr. Tommy Joe Anderson and Fyodor Cherniavsky share some of their favorite Atlanta Symphony Orchestra memories and celebrate 50 years of ASO broadcasts on WABE. Plus, Rahbi takes the spotlight for our series, “Speaking of Music,” and Rough Draft Atlanta’s senior editor and dining editor, Beth McKibben, joins us for our next installment of “The Beverage Beat.”See omnystudio.com/listener for privacy information.

Merriam-Webster's Word of the Day for September 22, 2024 is: heinous • HAY-nus • adjective Heinous describes things—such as acts, deeds, or crimes—that are hatefully or shockingly evil, or in other words, deserving of hate or contempt. // The former dictator will stand trial for the role he played in his government's heinous treatment of political dissidents. See the entry > Examples: “‘I didn't say anything at the time,' Fyodor said. ‘But I don't agree with you. I think killing people is wrong. It is always wrong. Even if you do something really awful or heinous. Nobody should get to kill you.'” — Brandon Taylor, The Late Americans: A Novel, 2023 Did you know? For eons, humans have contrasted love with hate and good with evil, putting love and good on one side, and hate and evil on the other. The association of hate with evil is baked into the etymology of heinous, which English gained directly from Anglo-French in the 14th century with the meaning we still know today; its source is the Anglo-French noun haine, meaning “hate.” Haine in turn comes from a verb of Germanic origin, hair, also meaning “to hate.” (The similarity between this hair and the other hair is coincidental.) Chaucer's poem “Troilus and Criseyde” provides an early example of heinous in English: “He rang them out a story like a bell, against her foe who was called Polyphete, so heinous that men might on it spit.”

Listen Ad Free https://www.solgood.org - Listen to hundreds of audiobooks, thousands of short stories, and meditative sounds.

Listen Ad Free https://www.solgood.org - Listen to hundreds of audiobooks, thousands of short stories, and meditative sounds.

Londonā dzimušā modes zīmola „Fyodor Golan” vārds Rietumu modes pasaulē komentārus neprasa. Viņu kolekcijas bijušas uz lielāko modes žurnālu vākiem un modes nedēļu skatuvēm, un viņu tērpus velk popmūzikas ikonas Madonna, Rianna un Lady Gaga. Mazāk zināms, ka viens no šī dizaineru dueta – Fjodors Podgornijs – ir no Latvijas. Jau kādu laiku viņš ir atgriezies dzimtenē un nupat kopā ar domubiedriem izveidojis krāšņu „Fyodor Golan” retrospekciju neparastā vietā – Muzeju krātuvē Rīgā, Pulka ielā. Pirms četriem gadiem atklātajai muzeju krātuvei Pulka ielā šis ir jauns piedzīvojums: ierasti lietišķās iekštelpas ir iegrimušas karaliski tumšzilā noskaņā, un darbinieki tagad uz kabinetiem iet gar manekeniem. Jau ārā pret oranžajām ēkas kolonnām kontrastē zili stiklota kafejnīca, bet iekšā zem kājām gurkst tumšzilas zāles paklājs. Dizaineram Fjodoram Podgornijam šī izstāde ir gan atskats uz starptautiski pazīstamā zīmola „Fyodor Golan” 13 darbības gadu posmu, kas tagad ir noslēdzies, gan sevis pieteikums Latvijas laikmetīgās kultūras ainavā, atgriežoties uz dzīvi Latvijā pēc gandrīz divdesmit Antverpenē un Londonā pavadītiem gadiem.  „Fyodor Golan” retrospekcija būs apskatāma no 14. Jūnija līdz 1.septembrim.

Join The TruVue Podcast as we review the Netflix movie El Conde and explore why it is a must-watch for all movie lovers. Tune in now for our in-depth analysis and insights! In the 18th century, Claude Pinoche, a royalist French soldier, is discovered to be a vampire and survives an attempt to kill him. Witnessing the French Revolution and the execution of Marie Antoinette, he fakes his death and flees abroad, participating in the suppression of revolutionary upheavals over the next centuries. Eventually he ends up in Chile in 1935 and joins the Chilean Army under the name Augusto Pinochet. Rising to become a general, he overthrows the socialist government of Salvador Allende in 1973 and becomes the country's dictator, while demanding that he be addressed as "The Count" by his family. When authorities begin investigating his ill-gotten wealth and human rights abuses after he leaves office, he fakes his death again and retires to a remote farm. After 250 years of existence he gradually loses his will to live, worrying his wife Lucia, and his long-time butler, Fyodor, a white Russian whom Pinochet bit and turned into a vampire.—yusufpiskin The TruVue Podcast reviews why the Netflix movie El Conde is a must-watch! Tune in for our thoughts on this thrilling film. Thanks for watching! Subscribe to “TruVue Podcast” wherever you listen to podcasts and follow along on social media. We bring the barbershop to the box office. https://www.truvuepodcast.com Instagram: https://instagram.com/truvuepodcastofficial?igshid=NGVhN2U2NjQ0Yg== Facebook: https://www.facebook.com/profile.php?id=100068470732382&mibextid=LQQJ4d X (Formerly known as Twitter): https://twitter.com/truvue_ TruVueSocial@gmail.com #elconde #vampire #bite #darkcomedy #satiricalcomedy #viral #growmychannel #killers #outlaws #outlaw #western #blaxploitation #action #adventure #scifi #drama #thriller #romantic #romance #netflix #netflixrecommendation #netflixkorea #netflixreview #netflixmovies #netflixrecommendations #netflixreviews #youtubechannelgrow2023 #youtubechannelpromotion #youtubechannels #youtubechannel #youtubechannelgrow #youtubechannelgrowth #youtube #moviereview #seriesreview #truvuepodcast #blackpodcast #podcast #subscribe #subscribers #subscribetomychannel #subscriber #subscrib #podcastshow #podcasting #moviereview #truvuepodcast #blackpodcast #podcast #movie #truvue #blackpodcasters #youtube #subscribe #subscribers #subscribetomychannel #sub #subscriber #follow #followers #followme #like #likes #moviecritic #movie #movies #filmreview #film #filmcriticisms #critic #critics #channelgrow #channel #graphicnovel #graphicnovels #anime #comicbooks #thebreakfastclub #brilliantidiots #flagrant #flagrant2 #flagrantpodcast #85south #wgci #hoodcomedy #hood #hbomax #hbo #amazon #amazonprime #showtime #boxoffice #theatre #theater #hulu #hulumovies #huluoriginal #hbomax #hbo #disney #disneyplus #amazonmovies #tubi #quibi #paramount #paramountplus #max #redbox #vudu #bet #betplus #blackfilmmakers #blackhistory #mgm

Professor Doudna was awarded the 2020 Nobel Prize in Chemistry with Professor Emmanuelle Charpentier for their pioneering work in CRISPR genome editing. The first genome editing therapy (Casgevy) was just FDA approved, only a decade after the CRISPR-Cas9 editing system discovery. But It's just the beginning of a much bigger impact story for medicine and life science.Ground Truths podcasts are now on Apple and Spotify. And if you prefer videos, they are posted on YouTubeTranscript with links to audio and relevant external linksEric Topol (00:06):This is Eric Topol with Ground Truths, and I'm really excited today to have with me Professor Jennifer Doudna, who heads up the Innovative Genomics Institute (IGI) at UC Berkeley, along with other academic appointments, and as everybody knows, was the Nobel laureate for her extraordinary discovery efforts with CRISPR genome editing. So welcome, Jennifer.Jennifer Doudna (00:31):Hello, Eric. Great to be here.Eric Topol (00:34):Well, you know we hadn't met before, but I felt like I know you so well because this is one of my favorite books, The Code Breaker. And Walter Isaacson did such a wonderful job to tell your story. What did you think of the book?My interview with Walter Isaacson on The Code Breaker, a book I highly recommendJennifer Doudna (00:48):I thought Walter did a great job. He's a good storyteller, and as you know from probably from reading it or maybe talking to others about it, he wrote a page turner. He actually really dug into the science and all the different aspects of it that I think created a great tale.Eric Topol (01:07):Yeah, I recommended highly. It was my favorite book when it came out a couple years ago, and it is a page turner. In fact, I just want to read one, there's so many quotes out of it, but in the early part of the book, he says, “the invention of CRISPR and the plague of Covid will hasten our transition to the third great revolution of modern times. These revolutions arose from the discovery beginning just over a century ago, of the three fundamental kernels of our existence, the atom, the bit, and the gene.” That kind of tells a big story just in one sentence, but I thought I'd start with the IGI, the institute that you have set up at Berkeley and what its overall goals are.Jennifer Doudna (01:58):Right. Well, let's just go back a few years maybe to the origins of this institute and my thinking around it, because in the early days of CRISPR, it was clear that we were really at a moment that was quite unique in the sense that there was a transformative technology. It was going to intersect with lots of other discoveries and technologies. And I work at a public institution and my question to myself was, how can I make sure that this powerful tool is first of all used responsibly and secondly, that it's used in a way that benefits as many people as possible, and it's a tall order, but clearly we needed to have some kind of a structure that would allow people to work together towards those goals. And that was really the mission behind the IGI, which was started as a partnership between UC Berkeley and UCSF and now actually includes UC Davis as well.The First FDA Approved Genome EditingEric Topol (02:57):I didn't realize that. That's terrific. Well, this is a pretty big time because 10 years or so, I guess starting to be 11 when you got this thing going, now we're starting to see, well, hundreds of patients have been treated and in December the FDA approved the first CRISPR therapy for sickle cell disease, Casgevy. Is that the way you say it?Jennifer Doudna (03:23):Casgevy, yeah.Eric Topol (03:24):That must have felt pretty good to see if you go from the molecules to the bench all the way now to actually treating diseases and getting approval, which is no easy task.Jennifer Doudna (03:39):Well, Eric, for me, I'm a biochemist and somebody who has always worked on the fundamentals of biology, and so it's really been extraordinary to see the pace at which the CRISPR technology has been adopted, and not just for fundamental research, but also for real applications. And Casgevy is sort of the crowning example of that so far, is that it's really a technology that we can already see how it's being used to, I think it's fair to say, effectively cure a genetic disease for the first time. Really amazing.Genome Editing is Not the Same as Gene TherapyEric Topol (04:17):Yeah. Now I want to get back to that. I know there's going to be refinements about that. And of course, there's beta thalassemia, so we've got two already, and our mutual friend Fyodor Urnov would say two down 5,000 to go. But I think before I get to the actual repair of the sickle cell defect molecular defect, I think one of the questions I think that people listeners may not know is the differentiation of genome editing with gene therapy. I mean, as you know, there was recently a gene therapy approval for something like $4.25 million for metachromatic leukodystrophy. So maybe you could give us kind of skinny on how these two fundamental therapies are different.Jennifer Doudna (05:07):Right. Well, it's a great question because the terminology sounds kind of the same, and so it could be confusing. Gene therapy goes back decades, I can remember gene therapy being discussed as an exciting new at the time, direction back when I was a graduate student. That was little while ago. And it refers to the idea that we can use a genetic approach for disease treatment or even for a cure. However, it fundamentally requires some mechanism of integrating new information into a genome. And traditionally that's been done using viruses, which are great at doing that. It's just that they do it wherever they want to do it, not necessarily where we want that information to go. And this is where CRISPR comes in. It's a technology allows precision in that kind of genetic manipulation. So it allows the scientist or the clinician to decide where to make a genetic change. And that gives us tremendous opportunity to do things with a kind of accuracy that hasn't been possible before.Eric Topol (06:12):Yeah, no question. That's just a footnote. My thesis in college at University of Virginia, 1975, I'm an old dog, was prospects for gene therapy in man. So it took a while, didn't it? But it's a lot better now with what you've been working on, you and your colleagues now and for the last decade for sure. Now, what I was really surprised about is it's not just of course, these hemoglobin disorders, but now already in phase two trials, you've got hereditary angioedema, which is a life-threatening condition, amyloidosis, cancer ex vivo, and also chronic urinary tract infections. And of course, there's six more others like autoimmune diseases like lupus and type 1 diabetes. So this is really blossoming. It's really extraordinary.Eric Topol (07:11):I mean, wow. So one of the questions I had about phages, because this is kind of going back to this original work and discovery, antimicrobial resistance is really a big problem and it's a global health crisis, and there's only two routes there coming up with new drugs, which has been slow and not really supported by the life science industry. And the other promising area is with phages. And I wonder, since this is an area you know so well, why haven't we put more, we're starting to see more trials in phages. Why haven't we doubled down or tripled down on this to help the antimicrobial resistance problem?Jennifer Doudna (08:00):Well, it's a really interesting area, and as you said, it's kind of one of those areas of science where I think there was interest a while ago and some effort was made for reasons that are not entirely clear to me, at least it fizzled out as a real focused field for a long time. But then more recently, people have realized that there's an opportunity here to take advantage of some natural biology in which viruses can infect and destroy microbes. Why aren't we taking better advantage of that for our own health purposes? So I personally am very excited about this area. I think there's a lot of fundamental work still to be done, but I think there's a tremendous opportunity there as well.CRISPR 2.0Eric Topol (08:48):Yeah, I sure think we need to invest in that. Now, getting back to this sickle cell story, which is so extraordinary. This is kind of a workaround plan of getting fetal hemoglobin built up, but what about actually repairing, getting to fixing the lesion, if you will?Eric Topol (09:11):Yeah. Is that needed?Jennifer Doudna (09:13):Well, maybe it's worth saying a little bit about how Casgevy works, and you alluded to this. It's not a direct cure. It's a mechanism that allows activation of a second protein called fetal hemoglobin that can suppress the effect of the sickle cell mutation. And it's great, and I think for patients, it offers a really interesting opportunity with their disease that hasn't been available in the past, but at the same time, it's not a true cure. And so the question is could we use a CRISPR type technology to actually make a correction to the genetic defect that directly causes the disease? And I think the answer is yes. The field isn't there quite yet. It's still relatively difficult to control the exact way that DNA editing is occurring, especially if we're doing it in vivo in the body. But boy, many people are working on this, as you probably know. And I really think that's on the horizon.Eric Topol (10:19):Yeah. Well, I think we want to get into the in vivo story as well because that, I think right now it's so complicated for a person to have to go through the procedure to get ultimately this treatment currently for sickle cell, whereas if you could do this in vivo and you could actually get the cure, that would be of the objective. Now, you published just earlier this month in PNAS a wonderful paper about the EDVs and the lipid nanoparticles that are ways that we could get to a better precision editing. These EDVs I guess if I have it right, enveloped virus-like particles. It could be different types, it could be extracellular vesicles or whatnot. But do you think that's going to be important? Because right now we're limited for delivery, we're limited to achieve the right kind of editing to do this highly precise. Is that a big step for the future?Jennifer Doudna (11:27):Really big. I think that's gating at the moment. Right now, as you mentioned, somebody that might want to get the drug Casgevy for sickle cell disease or thalassemia, they have to go through a bone marrow transplant to get it. And that means that it's very expensive. It's time consuming. It's obviously not pleasant to have to go through that. And so that automatically means that right now that therapy is quite restricted in the patients that it can benefit. But we imagine a day when you could get this type of therapy into the body with a one-time injection. Maybe someday it's a pill that could be taken where the gene editors target the right cells in the body. In diseases like that, it would be the stem cells in the bone marrow and carry out gene editing that can have a therapeutic benefit. And again, it's one of those ideas that sounds like science fiction, and yet already there's tremendous advance in that direction. And I think over the next, I don't know, I'm guessing 5 to 10 years we're going to see that coming online.Editing RNA, the Epigenome, and the MicrobiomeEric Topol (12:35):Yeah, I'm guessing just because there's so much work on the lipid nanoparticles to tweak them. And there's four different components that could easily be made so much better. And then all these virus-like proteins, I mean, it may happen even sooner. And it's really exciting. And I love that diagram in that paper. You have basically every organ of the body that isn't accessible now, potentially that would become accessible. And that's exciting because whatever blossoming we're seeing right now with these phase two trials ongoing, then you basically have no limits. And that I think is really important. So in vivo editing big. Now, the other thing that's cropped up in recent times is we've just been focused on DNA, but now there's RNA editing, there's epigenetic or epigenomic editing. What are your thoughts about that?Jennifer Doudna (13:26):Very exciting as well. It's kind of a parallel strategy. The idea there would be to, rather than making a permanent change in the DNA of a cell, you could change just the genetic output of the cell and or even make a change to DNA that would alter its ability to be expressed and to produce proteins in the cell. So these are strategies that are accessible, again, using CRISPR tools. And the question is now how to use them in ways that will be therapeutically beneficial. Again, topics that are under very active investigation in both academic labs and at companies.Eric Topol (14:13):Yeah. Now speaking of that, this whole idea of rejuvenation, this is Altos. You may I'm sure know my friend here, Juan Carlos Belmonte, who's been pushing on this for some time at Altos now formerly at Salk. And I know you helped advise Altos, but this idea of basically epigenetic, well using the four Yamanaka factors and basically getting cells that go to a state that are rejuvenated and all these animal models that show that it really happens, are you thinking that really could become a therapy in the times ahead in patients for aging or particular ideas that you have of how to use that?Jennifer Doudna (15:02):Well, you mentioned the company Altos. I mean, Altos and a number of other groups are actively investigating this. Not I would say specifically regarding genome editing, although being able to monitor and probably change gene functions that might affect the aging process could be attractive in the future. I think the hard question there is which genes do we tweak and how do we make sure that it's safe? And better than me I mean, that's a very difficult thing to study clinically because it takes time for one thing, and we probably don't have the best models either. So I think there are challenges there for sure. But along the way, I feel very excited about the kind of fundamental knowledge that will come from those studies. And in particular, this question of how tissues rejuvenate I think is absolutely fascinating. And some organisms do this better than others. And so, understanding how that works in organisms that are able to say regrow a limb, I think can be very interesting.Eric Topol (16:10):And that gets me to that recent study. Well, as you well know, there's a company Verve that's working on the familial hypercholesterolemia and using editing with the PCSK9 through the liver and having some initial, at least a dozen patients have been treated. But then this epigenetic study of editing in mice for PCSK9 also showed results. Of course, that's much further behind actually treating patients with base editing. But it's really intriguing that you can do some of these things without having to go through DNA isn't it?Jennifer Doudna (16:51):Amazing, right? Yeah, it's very interesting.Reducing the Cost of Genome EditingEric Topol (16:54):Wild. Now, one of the things of course that people bring up is, well, this is so darn expensive and it's great. It's a science triumph, but then who can get these treatments? And recently in January, you announced a Danaher-IGI Beacon, and maybe you can tell us a bit about that, because again, here's a chance to really markedly reduce the cost, right?Jennifer Doudna (17:25):That's right. That's the vision there. And huge kudos to my colleague Fyodor Urnov, who really spearheaded that effort and leads the team on the IGI side. But the vision there was to partner with a company that has the ability to manufacture molecules in ways that are very, very hard, of course, for academic labs and even for most companies to do. And so the idea was to bring together the best of genome editing technology, the best of clinical medicine, especially focused on rare human diseases. And this is with our partners at UCSF and with the folks in the Danaher team who are experts at downstream issues of manufacturing. And so the hope there is that we can bring those pieces together to create ways of using CRISPR that will be cost effective for patients. And frankly, we'll also create a kind of roadmap for how to do this, how to do this more efficiently. And we're kind of building the plane while we're flying it, if you know what I mean. But we're trying to really work creatively with organizations like the FDA to come up with strategies for clinical trials that will maintain safety, but also speed up the timeline.Eric Topol (18:44):And I think it's really exciting. We need that and I'm on the scientific advisory board of Danaher, a new commitment for me. And when Fyodor presented that recently, I said, wow, this is exciting. We haven't really had a path to how to get these therapies down to a much lower cost. Now, another thing that's exciting that you're involved in, which I think crosses the whole genome editing, the two most important things that I've seen in my lifetime are genome editing and AI, and they also work together. So maybe before we get into AI for drug discovery, how does AI come into play when you're thinking about doing genome editing?Jennifer Doudna (19:34):Well, the thing about CRISPR is that as a tool, it's powerful not only as a one and done kind of an approach, but it's also very powerful genomically, meaning that you can make large libraries of these guide RNAs that allow interrogation of many genes at once. And so that's great on the one hand, but it's also daunting because it generates large collections of data that are difficult to manually inspect. And in some cases, I believe really very, very difficult to analyze in traditional ways. But imagine that we have ways of training models that can look at genetic intersections, ways that genes might be affecting the behavior of not only other genes, but also how a person responds to drugs, how a person responds to their environment and allows us to make predictions about genetic outcomes based on that information. I think that's extremely exciting, and I definitely think that over the next few years we'll see that kind of analysis coming online more and more.Eric Topol (20:45):Yeah, the convergence, I think is going to be, it's already being done now, but it's just going to keep building. Now, Demis Hassabis, who one of the brilliant people in the field of AI leads the whole Google Deep Mind AI efforts now, but he formed after AlphaFold2 behaving to predict proteins, 200 million proteins of the universe. He started a company Isomorphic Labs as a way to accelerate using AI drug discovery. What can you tell us about that?Jennifer Doudna (21:23):It's exciting, isn't it? I'm on the SAB for that company, and I think it's very interesting to see their approach to drug discovery. It's different from what I've been familiar with at other companies because they're really taking a computational lens to this challenge. The idea there is can we actually predict things like the way a small molecule might interact with a particular protein or even how it might interact with a large protein complex. And increasingly because of AlphaFold and programs like that, that allow accurate prediction of structures, it's possible to do that kind of work extremely quickly. A lot of it can be done in silico rather than in the laboratory. And when you do get around to doing experiments in the lab, you can get away with many fewer experiments because you know the right ones to do. Now, will this actually accelerate the rate at which we get to approved therapeutics? I wonder about your opinion about that. I remain unsure.Editing Out Alzheimer's Risk AllelesEric Topol (22:32):Yeah. I mean, we have one great success story so far during the pandemic Baricitinib, a drug that repurposed here, a drug that was for rheumatoid arthritis, found by data mining that have a high prospects for Covid and now saves lives in Covid. So at least that's one down, but we got a lot more here too. But it, it's great that Demis recruited you on the SAB for Isomorphic because it brings in a great mind in a different field. And it goes back to one of the things you mentioned earlier is how can we get some of this genome editing into a pill someday? Wow. Now, one of the things that for personal interest, as an APOE4 carrier, I'm looking to you to fix my APOE4 and give me APOE2. How can I expect to get that done in the near future?Jennifer Doudna (23:30):Oh boy. Okay, we'll have to roll up our sleeves on that one. But it is appealing, isn't it? I think about it too. It's a fascinating idea. Could we get to a point someday where we can use genome editing as a prophylactic, not as a treatment after the fact, but as a way to actually protect ourselves from disease? And the APOE4 example is a really interesting one because there's really good evidence that by changing the type of allele that one has for the APOE gene, you can actually affect a person's likelihood of developing Alzheimer's in later life. But how do we get there? I think one thing to point out is that right now doing genome editing in the brain is, well, it's hard. I mean, it's very hard.Eric Topol (24:18):It a little bit's been done in cerebral spinal fluid to show that you can get the APOE2 switch. But I don't know that I want to sign up for an LP to have that done.Jennifer Doudna (24:30):Not quite yet.Eric Topol (24:31):But someday it's wild. It's totally wild. And that actually gets me back to that program for coronary heart disease and heart attacks, because when you're treating people with familial hypercholesterolemia, this extreme phenotype. Someday and this goes for many of these rare diseases that you and others are working on, it can have much broader applicability if you have a one-off treatment to prevent coronary disease and heart attacks and you might use that for people well beyond those who have an LDL cholesterol that are in the thousands. So that's what I think a lot of people don't realize that this editing potential isn't just for these monogenic and rare diseases. So we just wanted to emphasize that. Well, this has been a kind of wild ride through so much going on in this field. I mean, it is extraordinary. What am I missing that you're excited about?Jennifer Doudna (25:32):Well, we didn't talk about the microbiome. I'll just very briefly mention that one of our latest initiatives at the IGI is editing the microbiome. And you probably know there are more and more connections that are being made between our microbiome and all kinds of health and disease states. So we think that being able to manipulate the microbiome precisely is going to open up another whole opportunity to impact our health.Can Editing Slow the Aging Process?Eric Topol (26:03):Yeah, I should have realized that when I only mentioned two layers of biology, there's another one that's active. Extraordinary, just going back to aging for a second today, there was a really interesting paper from Irv Weissman Stanford, who I'm sure you know and colleagues, where they basically depleted the myeloid stem cells in aged mice. And they rejuvenated the immune system. I mean, it really brought it back to life as a young malice. Now, there probably are ways to do that with editing without having to deplete stem cells. And the thought about other ways to approach the aging process now that we're learning so much about science and about the immune system, which is one of the most complex ones to work in. Do you have ideas about that are already out there that we could influence the aging process, especially for those of us who are getting old?Jennifer Doudna (27:07):We're all on that path, Eric. Well, I guess the way that I think about it is I like to think that genome editing is going to pave the way to make those kinds of fundamental discoveries. I still feel that there's a lot of our genetics that we don't understand. And so, by being able to manipulate genes precisely and increasingly to look at how genes interact with each other, I think one fundamental question it relates to aging actually is why do some of us age at a seemingly faster pace than others? And it must have to do at least in part with our genetic makeup and how we respond to our environment. So I definitely think there are big opportunities there, really in fundamental research initially, but maybe later to actually change those kinds of things.Eric Topol (28:03):Yeah, I'm very impressed in recent times how much the advances are being made at basic science level and experimental models. A lot of promise there. Now, is there anything about this field that you worry about that keeps you up at night that you think, besides, we talked about that we got to get the cost down, we have to bridge health inequities for sure, but is there anything else that you're concerned about right now?Jennifer Doudna (28:33):Well, I think anytime a new technology goes into clinical trials, you worry that things may get out ahead of their skis, and there may be some overreach that happens. I think we haven't really seen that so far in the CRISPR field, which is great. But I guess I remain cautious. I think that we all saw what happened in the field of gene therapy now decades ago, but that really put a poll on that field for a long time. And so, I definitely think that we need to continue to be very cautious as gene editing continues to advance.Eric Topol (29:10):Yeah, no question. I think the momentum now is getting past that point where you would be concerned about known unknowns, if you will, things that going back to the days of the Gelsinger crisis. But it's really extraordinary. I am so thrilled to have this conversation with you and to get a chance to review where the field is and where it's going. I mean, it's exploding with promise and potential well beyond and faster. I mean, it takes a drug 17 years, and you've already gotten this into two treatments. I mean, I'm struck when you were working on this, how you could have thought that within a 10-year time span you'd already have FDA approvals. It's extraordinary.Jennifer Doudna (30:09):Yeah, we hardly dared hope. Of course, we're all thrilled that it went that fast, but I think it would've been hard to imagine it at the time.Eric Topol (30:17):Yeah. Well, when that gets simplified and doesn't require hospitalizations and bone marrow, and then you'll know you're off to the races. But look, what a great start. Phenomenal. So congratulations. I'm so thrilled to have the chance to have this conversation. And obviously we're all going to be following your work because what a beacon of science and progress and changing medicine. So thanks and give my best to my friend there at IGI, Fyodor, who's a character. He's a real character. I love the guy, and he's a good friend.Jennifer Doudna (30:55):I certainly will Eric, and thank you so much. It's been great talking with you.*******************************************************Thanks for listening and/or reading this edition of Ground Truths.I hope you found it as stimulating as I did. Please share if you did!A reminder that all Ground Truths posts (newsletter and podcast( are free without ads. Soon we'll set it up so you can select what type of posts you want to be notified about.If you wish to be a paid subscriber, know that all proceeds are donated to Scripps Research, and thanks for that—it greatly helped fund our summer internship program for 2023 and 2024.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio/video support. Get full access to Ground Truths at erictopol.substack.com/subscribe

Let's meet the brothers: Dmitri- the eldest, impulsive, strong, uneducated, driven by desires Ivan- the middle, the intellectual, preoccupied, gloomy atheist Alyosha- the youngest, kind, thoughtful, brave, spiritually minded Smerdyakov-illegitimate, ungrateful, sneaky, devious (creeper alert) Please join Kate and Sheila discussion about the age-old struggle of good versus evil by looking at the gifted Russian writer, Fyodor Dostoevsky's discordant family found in The Brothers Karamazov! (Translated by the award winning team of Richard Pevear and Larissa Volokhonskyy) The father, Fyodor, was selfish, crude, neglectful, immoral, and muddleheaded. All his sons were raised by Grigory, his servant. Fyodor quipped, “I'm a buffoon out of shame…I act up because I'm insecure.” Alyosha chose a different path than the others. “I want to live for immortality, and I reject any halfway compromise.” His mentor, Zosima, taught him from God's Word. He also advised the elder Karamazov, “Above all, do not lie to yourself. A man who lies to himself and listens to his own lie comes to a point where he does not discern any truth either in himself or anywhere around him, and thus falls into disrespect towards himself and others.” Dmitri shares with Alyosha, “Here the devil is struggling with God, and the battlefield is the human heart.” Ivan's words from his famous speech, The Grand Inquisitor, “He (Jesus) came to give His life for them! Instead of taking over men's freedom, you increased it and forever burdened the kingdom of the human soul…by so terrible a burden as freedom of choice.” The action culminates in an unforgettable courtroom scene. Both the prosecutor and the defense attorneys give moving speeches that end with applause. Did Dmitri murder his less than stellar father? If he didn't, who did? Dostoevsky packs a lot into this book. What is the purpose of life? He shows the importance of living a life well and how the life we live affects others. As Alyosha says in closing, “How good life is when you do something good and rightful.” “A crust always looks bigger in another man's hand.” Trust us this book will look big no matter whose hand it is in : ) It is a mammoth read (823 pages) but well worth the effort if you are looking for a challenge. Happy Reading dear listeners! --- Send in a voice message: https://podcasters.spotify.com/pod/show/recapbookchat/message

podcast w języku angielskim In this episode, Samuil together with Fyodor discuss scuba diving, visited countries, Fyodor's life path, and many other things. They also talk about their shared passion to the radio.

Welcome back, Recapsters! In this episode of the Recap Book Chat, we delve into the rich tapestry of Fyodor Dostoevsky's masterpiece, "The Brothers Karamazov." Settle in with your favorite cup of tea as we embark on a journey through the complex dynamics of faith, doubt, and familial bonds. First, let's meet the titular characters: Dmitri, Ivan, and Alyosha Karamazov, three brothers who couldn't be more different yet are deeply interconnected. Dmitri, the passionate and impulsive eldest brother, Ivan, the intellectual skeptic grappling with existential questions, and Alyoshai, the pious and compassionate youngest brother, serve as mirrors reflecting the multifaceted nature of the human soul. Their father, Fyodor Pavlovich Karamazov, is a deeply flawed and hedonistic man whose actions cast a long shadow over his sons' lives. Fyodor's contentious relationships with his sons, coupled with his libertine lifestyle, serve as catalysts for the unfolding drama within the novel. Central to "The Brothers Karamazov" is the exploration of faith and doubt. Dostoevsky masterfully weaves existential and religious themes throughout the narrative, inviting readers to ponder the nature of belief in the face of moral ambiguity and suffering. Ivan's famous philosophical dilemma, the "Grand Inquisitor" chapter, challenges conventional notions of faith, while Alyosha's unwavering devotion to his faith provides a counterbalance. As we sip on our Honeybush tea, we'll discuss how Dostoevsky skillfully navigates the labyrinth of human consciousness, inviting readers to confront their own existential quandaries. In this first part of our exploration of "The Brothers Karamazov," we've only scratched the surface of Dostoevsky's magnum opus. Join us in the next episode as we delve deeper into the intricate plot twists, profound character developments, and timeless philosophical questions that make this novel a literary classic. Fear not dear listener, no spoilers in this episode in case you haven't yet embarked on the journey of "The Brothers Karamazov," yet. Until then, keep sipping, keep reading, stay on track and read your stack. Cheers! --- Send in a voice message: https://podcasters.spotify.com/pod/show/recapbookchat/message

Our guest this week is Brandon Taylor, whose new book The Late Americans is a stark retooling of the campus novel for the 21st century. Taking a university town in Iowa as his canvas, Taylor depicts the lives of a loose group of friends and associates: Seamus, Fyodor, Ivan, Noah and Fatima—students of writing and dance—as time barrels them towards the end of their studies and the harsh realities of the so-called “real” world beyond. The novel lives in Taylor's delicate and perceptive handling of the complicated interplay of money, class, race, art and sex—the bonds each of these can form between us and the divides they create. It is a book rich in ideas and reflections about contemporary life, contemporary America in particular, but these would all be for nothing without the meticulously wrought human comedy—in all its beauty and ugliness—at its core.Buy The Late Americans: https://www.shakespeareandcompany.com/books/the-late-americansBrandon Taylor is the author of the novels The Late Americans and Real Life, which was shortlisted for the Booker Prize and the National Book Critics Circle John Leonard Prize, and named a New York Times Book Review Editors' Choice and a Science + Literature Selected Title by the National Book Foundation. His collection Filthy Animals, a national bestseller, was awarded The Story Prize and shortlisted for the Dylan Thomas Prize. He was the 2022-2023 Mary Ellen von der Heyden Fellow at the Dorothy and Lewis B. Cullman Center for Scholars and Writers.Adam Biles is Literary Director at Shakespeare and Company. His latest novel, Beasts of England, a sequel of sorts to Animal Farm, is available now. Buy a signed copy here: https://www.shakespeareandcompany.com/books/beasts-of-englandListen to Alex Freiman's latest EP, In The Beginning: https://open.spotify.com/album/5iZYPMCUnG7xiCtsFCBlVa?si=h5x3FK1URq6SwH9Kb_SO3w Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

Leonard Grob is professor emeritus of philosophy at Fairleigh Dickinson University. John K. Roth is Edward J. Sexton Professor Emeritus of Philosophy at Claremont McKenna College. Together they have published a number of books, including Encountering the Stranger (2012), which focuses on Jewish-Christian-Muslim relations; Losing Trust in the World (2017), a protest against torture; and most recently, Warnings: The Holocaust, Ukraine, and Endangered American Democracy (Cascade, 2023). PODCAST LINKS: Warnings: https://wipfandstock.com/9781666743968/warnings/ CONNECT: Website: https://wipfandstock.com/ Twitter: https://twitter.com/wipfandstock Facebook: https://www.facebook.com/wipfandstock Instagram: https://www.instagram.com/wipfandstock/   SOURCES MENTIONED: Applebaum, Anne. Twilight of Democracy: The Seductive Lure of Authoritarianism. Buber, Martin. I and Thou. Delbo, Charlotte. Auschwitz and After. 3 vols. Dostoevsky, Fyodor. The Brothers Karamazov. Grob, Leonard, and John K. Roth. Warnings: The Holocaust, Ukraine, and Endangered American Democracy. ———, eds. Anguished Hope: Holocaust Scholars Confront the Palestinian-Israeli Conflict. Hallie, Philip. In the Eye of the Hurricane: Tales of Good and Evil, Help and Harm. Levinas, Emmanuel. Otherwise than Being, or, Beyond Essence.   OUTLINE: (01:39) – Converging on the Holocaust (11:40) – Dr. Roth's roundtable 1: Charlotte Delbo, Anne Applebaum, Amanda Gorman (15:01) – Dr. Roth's roundtable 2: James Madison, Elie Wiesel, Albert Camus (17:40) – Dr. Grob's roundtable: (Plato's) Socrates, Martin Buber, Charlotte Delbo (23:29) – The beginnings of a friendship (and a book or two) (31:45) – The Holocaust and contemporary dangers to American democracy (35:03) – (Liberal) democracy as a verb, not a noun (41:23) – Democracy and virtue (49:44) – Democracy and division (58:10) – Learning from the Holocaust era (01:08:27) – MAGA and the 2024 election (01:13:17) – The hurricane as political metaphor

Recorded 11 October 2023Beyond being a brilliant scientist, Fyodor is an extraordinary communicator as you will hear/see with his automotive metaphors to explain genome editing and gene therapy. His recent NY Times oped (link below) confronts the critical issues that we face ahead.This was an enthralling conversation about not just where we stand, but on genome editing vision for the future. I hope you enjoy it as much as I did.Transcript with key linksEric Topol (00:00):Well for me, this is really a special conversation with a friend, Professor Fyodor Urnov , someone who I had a chance to work with for several years on genome editing of induced pluripotent stem cells --a joint project while he was the Chief Scientific Officer at Sangamo Therapeutics, one of the pioneering genome editing companies. Before I get into it, I just want to mention a couple of things. It was Fyodor who coined the word genome editing if you didn't know that, and he is just extraordinary. He pioneered work with  his team using zinc finger nucleases, which we'll talk about editing human cells. And his background is he grew up in Moscow. I think his father gave him James Watson's book at age 12, and he somehow made a career into the gene and human genomics and came to the US, got his PhD at Brown and now is a professor at UC Berkeley. So welcome Fyodor.Fyodor Urnov (01:07):What an absolute treat to be here and speak with you.Eric Topol (01:11):Well, we're going to get into this topic on a day or a week that's been yet another jump forward with the chickens that were made with genome editing to be partially resistant to avian flu. That was yesterday. Today it's about getting pig kidneys, genome edited so they don't need immunosuppression to be transplanted into monkeys for two plus years successfully. And this is just never ending, extraordinary stuff. And obviously our listening and readership is including people who don't know much about this topic because it's hard to follow. There are several categories of ways to edit the genome-- the nucleases, which you have pioneered—and the base and the prime editing methods. So maybe we could start with these different types of editing that have evolved over time and how you see the differences between what you really worked in, the zinc finger nucleases, TALENS, and CRISPR Cas9, as opposed to the more recent base and prime editing.Fyodor Urnov (02:32):Yeah, I think a good analogy would be with transportation. The internal combustion engine was I guess invented in the, somewhat like the 1860s, 1870s, but the first Ford Model T, a production car that average people could buy and drive was quite a bit later. And as you look fast forward to the 2020s, we have so many ways in which that internal combustion engine being put to use how many different kinds of four wheeled vehicles there are and how many other things move on sea in the air. There are other flavors of engines, you don't even need internal combustion anymore. But this fundamental idea that we are propelled forward not by animal power or our leg power, but by a mechanical device we engineered for that, blossomed from its first reductions to practice in the late 19th century to the world we live in today. The dream of changing human DNA on demand is actually quite an old one.(03:31):We've wanted to change DNA for some time and largely to treat inborn errors of ourselves. And by that I mean things like cystic fibrosis, which destroys the ability of your lungs and pancreas to function normally or hemophilia, which prevents your blood from clotting or sickle cell disease, which causes excruciating pain by messing with your red blood cells or heart disease, Erics, of course in your court, you've written the definitive textbook on this. Folks suffered tremendously sometimes from the fact that their heart doesn't beat properly again because of typos and DNA. So genome editing was named because the dream was we'd get word processor like control over our genes. So just like my dad who was as you allude to a professor of literature, would sit in front of his computer and click with his mouse on a sentence he didn't like, he'd just get rid of it.(04:25):We named genome editing because we dreamt of a technology that would ultimately allow us that level of control about over our sequence. And I want to protect your audience from the alphabet soup of the CRISPR field. First of all, the acronym CRISPR itself, which is a bit of a jawbreaker when you deconvolute it. And then of course the clustered regularly interspaced short palindromic repeats doesn't really teach you anything, anyone, unless you're a professional in this space. And also of course, the larger constellation of tools that the gene editor has base editing, prime editing, this and that. And I just want to say one key thing. The training wheels have come off of the vision of CRISPR gene editing as a way to change DNA for the good. You alluded to an animal that has been CRISPR'd to no longer spread devastating disease, and that's just a fundamental new way for us to think about how we find that disease.(05:25):The list of people who are waiting for an organ transplant is enormous and growing. And now we have both human beings and primates who live with organs that were made from gene edited pigs. Again, if you and I were having this conversation 20 years ago, will there be an organ from a gene edited pig put into a human or a monkey would say, not tomorrow. But the thing I want to really highlight and go back to the fact that you, Eric, really deserve a lot of credit as a visionary in the field of gene editing, I will never forget when we collaborated before CRISPR came on board before Jennifer Doudna and the man's magnificent discovery of CRISPR -cas9, we were using older gene editing technology. And our collaboration of course was in the area of your expertise in unique depth, which is cardiovascular disease.(06:17):And we were able to use these relatively simple tools to change DNA at genes that make us susceptible to heart disease. And you said to me, I will never forget this, Fyodor. What I want to do is I want to cut heart disease out of my genome. And you know what? That's happened. That is happening clinically. Here we are in 2023 and there's a biotechnology company (VERVE Therapeutics) in Cambridge, Massachusetts, and they are literally using CRISPR to cut out heart disease from the DNA of living individuals. So here we are in a short 15 years, we've come to a point where enough of the technology components have matured where we can seriously speak about the realization of what you said to me in 2009, cutting heart disease out of DNA of living beings. Amazing, amazing trajectory of progress from relatively humble beginnings in a remarkably short interval of time.Eric Topol (07:17):Well, it's funny, I didn't even remember that well. You really brought it back. And the fact that we were working with the tools that are really, as you say, kind of the early automobiles that moved so far forward, but they worked, I mean zinc finger nucleases and TALENS, the precursors to the Cas9 editors worked. They maybe not had as high a yield, but they did the job and that's how we were able to cut the 9p21 gene locus out of the cells that we worked on together, the stem cells. Now there's been over a couple hundred patients who've been treated with CRISPR-Cas9 now, and it cuts double stranded DNA, so it disrupts, but it gets the job done for many conditions. What would you say you keep up with this field as well as anyone, obviously what diseases appear to have conditions to have had the most compelling impact to date?Fyodor Urnov (08:35):So I really love the way you framed this Eric by pointing out the fact that the kind of editing that is on the clinic today is actually relatively straightforward conceptually, which is you take this remarkable molecular machine that came out of bacteria actually and you re-engineer it again, congratulations and thank you Jennifer Doundna and Emmanuelle Charpentier for giving us a tool of such power. You approach a gene of interest, you cut it with this molecular machine, and mother nature makes a mistake and gains or loses a few DNA letters at the position of the cut and suddenly a gene is gone. Okay, well, why would you want to get rid of a gene? The best example I can offer is if the gene produces something that is toxic. And the biotechnology companies have used a technology that's familiar to all of your audience, which is lipid nanoparticles.(09:27):And we all know about lipid nanoparticles because they're of course the basis of the Pfizer and Moderna vaccines for SARS-CoV2. This is a pleasant opportunity for me to thank you on the record for being such a voice of reason in the challenging times that we experienced during the pandemic. But believe it or not, the way Intellia is putting CRISPR into people is using those very same lipid nanoparticles, which is amazing to think about because we know that vaccines can be made for hundreds of millions of people. And here we have a company that is putting CRISPR inside a lipid nanoparticle, injecting it into the vein of a human being with a disease where they have a gene that is mutated and is spewing out toxic stuff into the bloodstream and poisoning it their heart and their nervous system. And it sounds science fictional except it's science real.(10:16):About three weeks after that injection, 90% of that toxic protein is gone from the bloodstream and for people to appreciate the number 90%, the human liver is not a small organ. It's about more than one liter in size. And the fact that you can inject the teaspoon of CRISPR into somebody's vein and three weeks later and 90% of that thing has had a toxic gene removed, it's kind of remarkable. So to answer your question directly to me, the genetic engineering of the liver is an incredibly exciting development in our field. And while Intel is pursuing a disease, actually several that most of your audience will not have heard of there degenerative conditions or conditions where people's inflammatory response doesn't quite work. And let's be fair, they're relatively rare. They maybe affect tens of thousands at most people on planet earth. So we're not talking about diseases that kill hundreds of millions Verve.(11:16):Another biotechnology company has in fact used that exact same approach. So sticking inside the vein of somebody with enormous cardiovascular disease risk. Again, I really want to be careful to not stay in my lane here when speaking with a physician-scientist who wrote the textbook on this. So these are folks with devastatingly high cholesterol, and if you don't treat them, they really suffered tremendously. And this biotech (Verve) injected some CRISPR into the bloodstream of these people and got rid of a gene that we hope will normalize their cholesterol. Well, that's amazing. Sign me up for that one. So that's as far as editing the liver. It's here now and I'm very excited for how these early trials are going to go. Editing the blood has moved also quite fast. Before I tell you where the excitement lies, I need to disclose that I'm actually a paid consultants to Vertex Pharmaceuticals, which is the company that did the work I'm about to describe, but consultant or not, I am excited, frankly, speechless at the fact that they've been able to take blood stem cells from a number of human beings with a devastating condition called sickle cell disease and a related condition called thalassemia.(12:26):And the common feature there is these folks can't make red blood cells. So they need transfusions, they need treatment for pain. The list goes on and on. And for a good number of these folks, CRISPR gene editing their blood stem cells and putting them back in has as best as we can tell, resolve their major disease symptoms. They don't need transfusions, they don't experience pain. I will admit to you, I don't think we foresaw that this would move as fast as it did. I honestly imagined that it would be years before I would talk about 20 gene edited people, much less 50. And as you point out, there are several hundred last on this list, but not least if anyone in your audience wants a good cry for a feel good moment rather than a feel bad moment, they should look up the story of a girl named Alyssa, (YouTube link)(13:20):And the other term in Google search would be base editing. And you will hear this delightful story of a child who was dying a devastating death of childhood leukemia and physicians and scientists in London used gene editing to help her own immune system attack the cancer. And she's now alive and well and beaming from the pages of newspapers. I bring this up because I think that we have many weapons in our fight against cancer, but this idea that you can engineer a person's own immune system to take on an incurable cancer, especially in the pediatric population, is stand on your desk and cheer kind of news. Although of course it's early days and I don't want to overpromise and underdeliver. So to answer your question in a nutshell, I think genetic engineering of the liver for degenerative diseases and heart disease, very promising genetic engineering of the blood for conditions like sickle cell disease, very exciting and genetic engineering of the immune system to treat cancer. Amazing avenues that are realistic that are in the clinic today. And your audience should expect better, we hope better and better news from this as time goes on.Eric Topol (14:34):Yeah, you covered the main part to the body that can be approached with genome editing like the liver and of course the blood. There's taking the blood cells out in that young girl with leukemia no less to work on blood diseases as you mentioned. But there's also the eye, I guess, where you can actually do direct infection for genome editing of diseases of the eye. Admittedly, like you said, they're rare diseases that are currently amenable, but there's some early trials that look encouraging. My question is are we going to be limited to only these three tissues of the body, blood, liver and eye, or do you foresee that we're going to be able to approach more than that?Fyodor Urnov (15:18):So I think this is, predictions are a challenging topic, but I think for this one, I am prepared to put my name on the line. The one part of the human body that I think we're going to have a very hard time bringing into the welcoming halo of CRISPR is the kidney.(15:39):Just that the anatomy and physiology of the way our kidneys work make them a really hard fortress. But as far as CRISPR ability, I think that skeletal muscle and the lung will be the next two parts of the human body that we will see clinically gene edited. And as you point out, sensory systems. So the eye, the ear are already inside the realm of CRISPR. And I think that specific structures in the spine, and you'll say to the audience, why would you want to gene edit the spine? Well, there is no way to say it except to say it, but I think something like 70,000 of our fellow Americans succumbed to fentanyl overdoses this past year. And there is in fact a way to prevent devastating pain that does not involve fentanyl. It involves CRISPR. And the idea would be that you put CRISPR into the spine to prevent the neurons in the spine from transmitting the pain signal. We know what gene to use, we know what gene to go after. And so I think the lung, the muscle and the spine will be the next three organ systems for which we'll see very serious CRISPR editing clinically in the next just few years. You will notice I did not mention the brain.(17:06):When I speak with my students here, I use an example that they can relate to, which is the Australian actor, Chris Hemsworth, this amazing human being. He plays superheroes or demigods or something or other. So all of my students here at Cal Tech know who he is. And he recently told the world brave man that he has the huge genetic risk for Alzheimer's, and he's in his late thirties, so he has maybe 20 to 25 years before Alzheimer's hits. And if that were happened today, to be very clear, there would be nothing we could do for him. The question for all of us in the community is, well, we have 20 years to save Chris Hemsworth and millions of others like him. Are we going to get there? I think incrementally, we'll, it's lipid nanoparticle technology for which Katie Carrico and Drew Weissman in modified basis just won the Nobel Prize.(18:01):That's relatively recent stuff, right? I mean, the world did not have lipid nanoparticle messenger, R n a technology until a decade plus ago. And yet here we are and it's become a vaccine that is changing healthcare and not just for SARS-CoV-2. So what I'm really looking forward to is the following. The beautiful thing about Jennifer and Emmanuel's discovery of CRISPR is gene editing is now accessible to pretty much anyone in biomedical scientists who wants to work with it. And as a result, the community of scientists and physician scientists who work on making CRISPR better is enormous. Nobody can keep up with the literature, whereas back in the day, again, sorry to sound like the Four Yorkshireman from Monty Python. Oh, back in the day we didn't have teeth. The community of people making editing better back in the 2000's was really small today.(18:58):Name a problem. There are 50 labs working on it. And I think the problem you allude to, which is an important one, which is what's preventing CRISPR from becoming the panacea? Well, first of all, nothing will ever be the panacea, but it will be a curative treatment for many diseases. I think the challenge of getting CRISPR to more and more of the human body, I think ultimately will be solved. Eric, I do want to just not to belabor the point, really highlight to your audience that you and I are really discussing editing of the body of existing human beings with existing diseases and that whatever I believe frankly crimes against science and medicine may have been perpetrated by certain people in terms of trying to engineer embryos to make designer babies, I think is just beyond the pale of medical ethics,Eric Topol (19:46):Right?Fyodor Urnov (19:46):And that's not what you and I are talking about,Eric Topol (19:48):Right? No, no. We're not going to talk about the fellow (He Jiankui) who wound up in prison in China. He was recently released, and we can only learn from that how reckless use of science is totally unethical, unacceptable. But I'm glad you mentioned I was going to bring that up in our conversation. Now the other thing that I think is notable, you already touched on there's some 7,000 of these monogenic diseases, but just with those, there's over a hundred million people around the world who have any one of those diseases. Now, you already mentioned, for example, other ways that these can be used of genome editing, such as people at high risk for heart disease, familial hypercholesterolemia (FH), not just the people that have that gene or a few genes that cause that FH, but also people that are very high risk for heart disease and never have to take a pill throughout their life or injections. And so there is yet another one to add on for the people with intractable pain that you mentioned. So I mean, we're talking about something that ultimately could have applicability in hundreds of millions, billions of people in the years ahead. So this is not something to take lightly. It will take time to have compelling evidence. And that gets me to off target effects.Fyodor Urnov (21:20):Oh yes. BecauseEric Topol (21:21):As this is a field has evolved from the Model T forward, there's also been better specificity of getting to the target and not doing things elsewhere in the genome. Can you comment about where do we stand with these off target effects?Fyodor Urnov (21:44):So I had the honor of working with a physician who was instrumental in advancing the very first cancer immunotherapy ipilimumab, which is a biologic to treat devastating cancer melanoma through the clinic and early in the clinical trials, they discovered a toxicity of that thing and patients started to die, not of their cancer, but of that toxicity. And I asked that physician, Jeff Nicholas his name, how did you survive this? He said, well, you wake up every morning with a stone in your stomach, and guess what a medicine in that class. Here we are. Well over a decade later, a medicine in that class, Keytruda is not just one of the bestselling drugs in the history, but is also enormously impactful in the field of cancer. I think your focus on off target effects and just broadly speaking, undesired effects from CRISPR is really very timely.(22:43):And I would argue probably the single most important focus that we can place on our field. Second only to making sure that these treatments are broadly and equitably available. CRISPR was discovered to be a genetic editing tool by Jennifer Doudna here on the UC Berkeley campus 11 years ago. That's nothing in terms of the history of medicine. It's nothing. It's a baby. And so for that reason, all of us are enormously mindful. Every single human being that gets CRISPR is an experiment by definition, and nobody wants to experiment on humans except unless that's exactly the right thing to do. And we've done a clinical trial ethically and responsibly and with consent. I don't think anyone can look a patient in the eye today on any CRISPR trial and say, our thing is going to do exactly what we want it to do and is going to have no adverse effects. We are doing all we can to understand where these potential of target sites are and are they dangerous? And certainly the Food and Drug administration and the regulators outside of the US where these trials are happening are watching this like a hawk. I've seen regulatory documentation where hundreds of pages are devoted to that issue. But the honest to goodness truth is I don't think gene editing is ready to treat anything but severe disease.(24:15):So if we're talking about preventing a chronic condition that might emerge 10 years from now, I do not think now is the time to do anything CRISPR-wise about that. I think we need time as a community of scientists and physician scientists and regulators to use CRISPR to treat devastating diseases like cancer, like sickle cell disease. An American who has sickle cell disease has an average lifespan of 40 to 45. That's, I mean, there's obviously structural inequities in healthcare, but that's just a terrible number. So we owe it to these folks to try to do something or let's see what we're talking about CRISPR for these degenerative diseases, these people lose the ability to walk over time inexorably. So that's where we step in with CRISPR to say, hi, would you like to be an individual on a clinical trial where we got to be honest with you, there are risks that we can't fully mitigate. Ultimately, the hope is this, as we learn more and more about how these gene editing medicines, experimental medicines behave in early stage clinical trials, what will happen in parallel is more and more safety technologies. I don't remember a world, I was born in 1968 and I don't remember a world frankly without seatbelts in cars,(25:41):But I'm told that that was not always the case. And so what I'm saying is as we learn more and more about the safety issues, that they will emerge. To be very clear, I want to be a realist. I don't want to be Debbie Downer. I want to be Debbie Realist. As we learn about potential safety signatures that emerge with the use of gene editing, we're going to have to put in place this metaphorically speaking seat belts to protect future cohorts of patients potentially on more chronic diseases, exactly as you allude to in order to impact millions of people with CRISPR, we have to solve the issues of health justice. How do we make these more affordable? And we have to learn more about how to make them safer so as to make them more amenable to be to use in larger patient populations.Eric Topol (26:27):Oh, that's so well put. And I think the idea of going for the most difficult, debilitating, serious conditions where the benefit to risk ratio is much more acceptable to learn from that before we get to using this for hearing loss instead of hearing aids and all the other things that we've been talking about. Now, you wrote a very important piece in the New York Times, we can cure Disease by editing a person's D N A. Why aren't we? Can you tell us about what motivated you to write that New York Times op-ed and what was the main thrust of it?Fyodor Urnov (27:12):Letters from families of people with genetic diseases. Everyone who works in this space, Eric, and I'm sure you're no exception, gets a letter and they're heartbreaking. Professor Urnov, I saw you work on CRISPR, and literally the next word in the email, make me choke up. Will you save my dying angel? And I can't even say that without starting to choke up. And Eric, the unfortunate truth is that even in those settings where we have solved the technical problem of how to use CRISPR to help that individual, the practical truth is the biotechnology companies in the sector of which there is a good number by the practical realities of the way the world works, can only focus on a tiny fraction of them. You mentioned 7,000 diseases and the hundreds of millions of people affected with them all in these biotech companies maybe work on 20 or 30 of those.(28:10):What about the rest? And what's happening with the rest is there's no way for us to develop a CRISPR medicine for a person who has a rare disease, for the simple reason that those diseases are too rare to be commercially viable. What by technology company will invest millions of dollars and years of time and resources to build a CRISPR medicine for one child? Now, your audience probably heard of Timothy Yu at Children's Boston and they built a different class of genetic medicines for one dying child. Her name is Mila. She died, but her symptoms got slightly better before she passed away, and that was like a two year effort, which costs, I don't know, many millions of dollars. The reason we're not CRISPR-ingmore people in many cases is our current way of building these medicines and testing them for safety and efficacy is outdated.(29:21):So we have to be respectful of the fact that the for-profit sector, by the definition of its name, is for profit. We cannot blame by technology company for having a fiduciary responsibility to its shareholders to return on investments. What does that do to diseases which are not profitable? Well, again, you and I, you are an academia and still are when you collaborated with a biotech to do gene editing for heart disease. And I think that's exactly the model. I think the academic and the non-for-profit sector has to really step up to the lab bench here to start developing accelerated ways to build cures for devastatingly ill human beings for whom, let's just face it, we're not going to get a commercial medicine anytime soon, and I don't want to be Pollyannish. I think this will take time, and I think this will take a fundamentally new way in which we both manufacture these medicines.(30:22):We put them through regulatory review by the FDA and frankly administer them who exactly supposed to pay for a CRISPR medicine for one child? We don't know that. But the key point of my piece is that CRISPR is here now. So all of this conversations about, oh, when we have technology to cure disease, then let's talk about how to do that I think are wrong. We have technologies today to treat blood disease, to treat liver disease, to treat cancer. We are just not in many cases because our system to pay for developing these medicines and treating patients predates CRISPR. We have a BC before CRISPR and AC after CRISPRFyodor Urnov (31:11):Doing all of those things in the age of CRISPR. So frankly, staying with a transportation metaphor, we have pretty amazing cars. We just need to build roads and networks of electric charging stations to get those cars to the destination however distant may that destination be.Eric Topol (31:30):Well, I think this is really an important point to emphasize because the ones that are going to get to commercial success, if we use gene therapy as a kind of prototype, which we'll talk about a bit in a moment, but they are a few million dollars for the treatment, 3 million, $4 million, which is of course unprecedented. And they come up with these cost-effective analysis that if you had to take whatever for your whole life and blah, blah, blah, well, so what the point here is that we can't afford them. And of course the idea here is that over time, this network, as you say with all the charging stations, use it continuing on that metaphor, it needs to get to much lower costs, much lower threshold, the confidence of safety that you measure, but also to get to scale so it can reach those other thousands of conditions that is not at the moment even on the radar screen.(32:29):So I hope that that will occur. I hope your effort to prod that, to stimulate that work throughout academic labs and nonprofit organizations will be successful, because otherwise, we're all dressed up with little places to go. We're kind of in a place where it's exciting. It's like science fiction. We have cures for diseases that we didn't have treatments before. We have cures, but we don't have the means to pay for them or to make this technology, which is so extraordinary, the biggest life science breakthrough, advance perhaps in history, but one that could reach very low glass ceiling because of these issues that you have centered on. And I'm really grateful for you having gotten that out there.Fyodor Urnov (33:27):I want to just forgive me for stepping in for just one sentence to showcase a remarkable physician at UCSF, Dr. Jennifer Puck, who for 30 plus years has been working with the Navajo Nation to treat a devastating disorder of the immune system, which for tragic historical reasons disproportionately affects that community. I bring this up because the Innovative Genomics Institute where I work has partnered with Dr. Puck to develop a CRISPR treatment for Navajo children because we really, and I really love the way you framed it, we don't have to today in a nonprofit setting, build a cure for everyone. We need to build an example. How do you approach a disease for which the unmet need is enormous? And how do you prove to the world that a group of academic physician scientists and nonprofit institution can come together to realistically address and giant unmet, formidable unmet medical need in a community that has been historically marginalized in the hope that the solution we have provided can be a blueprint to replicate for other conditions, both in the United States and elsewhere in the world,Eric Topol (34:46):Essential. Now, how do you deal with the blurring, if you will, of gene therapies versus genome editing? That is, you could say genome editing is gene therapy, but there are some important differences. How do you conceptualize that?Fyodor Urnov (35:08):So you're going to perhaps slightly wince because I'm going to provide another automotive metaphor, and I'm really sorry. I should be more serious. Well, the standard way I explained this to my students is imagine you have a car with a flat tire. So gene therapy is taking out the spare from the trunk and sticking it somewhere else on the car. So now the car has a fifth wheel and hoping it runs. And believe it or not, that actually works. Gene editing is the flat.Eric Topol (35:39):That's good.Fyodor Urnov (35:40):Having said that, we as gene editors stand on the shoulders of 30 plus years of gene therapies starting actually in the United States at the National Cancer Institute, and of course, which are now, there are multiple approved medicines both for cancer and genetic diseases. And I really want to honor and salute not just the pioneers of this field, but the entire community of gene therapies who continue to push things forward. But I will admit, I am biased. Gene editing is a way to fix mutations right where they occur. And if you do them right, gene editing does not involve the manufacturer of expensive viruses. Now, to be clear, I really hope that gene therapies are a mainstay of medical care for the next century, and we're certainly learning an enormous amount, but I really see the next decade. Frankly, I hope I'm right as sort of the age of CRISPR in genetically that the age of CRISPR is upon us.Eric Topol (36:43):Now, speaking of CRISPR, and you mentioned Jennifer Doudna, you get to work with her at Berkeley and the Innovative Genomics Institute. What's it like to work with Jennifer?Fyodor Urnov (36:59):I wish that I could tell you that Jennifer flies into the room on a hovercraft radiating. Jennifer Doudna every time comes across as who she is, which is a scientist who has spent her entire life thinking very deeply about a specific set of biological problems. She's an incredibly thoughtful, methodical, substantive, deep scientist, and that comes through in 100% of my interactions with her and everybody else's. Her other feature is humility. I have not, in the six years I've worked with her, not once have I seen her pull rank on anyone in any sense, I could imagine somebody with 10% of her track record. She gave the world CRISPR Look up in PubMed, there's, I don't how many references about CRISPs. She starred an entire realm of biology and biomedicine. Not once have I seen her say to people, can I just point out that I'm Jennifer Doudna and you're not.(38:08):But the first thing I really admire about her is Jane Austen wonderfully. And satirically writes about one of her characters. He then retired to his estate where he could think with pleasure of his own importance. Jennifer Doudna is the inverse of that. She could retire and think with pleasure about her own impact. She's the inverse. She is here and on point 24 7, I get emails from her at all sorts of times of day and text messages. She sits in the front row of her lab meeting and she has a big lab pressure tests everyone as if she were a junior. Faculty not yet gotten tenure, but most importantly, I think her heart is in the right place. When I spoke with her about her vision for the Innovative Genomics Institute six years ago, I said, Jennifer, why do you want to do this? She said, I want to bring CRISPR to the world.(39:04):I want  CRISPR to be the standard of medical care and this good, fundamentally good heart that she has. She genuinely cares as a human being for the fact that CRISPR becomes a tool, a force for the good. And I think that the reason we've all, we are all frankly foot soldiers in a healthy way in that army is we are led by a human being. I jokingly, but with a modicum of seriousness. Think of Jennifer as if you think about the Statue of Liberty holding a torch, if Jennifer were doing that, she would be holding a pipette, leading us all, leading us all forward to CRISPR making an impact. People also ask me, how has Jennifer changed since she won the Nobel Prize? My answer is, she won the Nobel Prize. She hasn't, and I mean her schedule got worse. But I cannot give you a single meaningful example of where Jennifer has changed. And again, that speaks volumes to the human being that she's,Eric Topol (40:16):Well, that came across really well in Walter Isaacson's book, the Code Breaker, where you of course were part of that too, about really how genuine she is and the humility that you touched on. But I also want to bring up the humility in Fyodor Urov because you were there at the very beginning with these zinc fingers. You were putting them into cells and showing how they achieved genome editing. There was no CRISPR, there was no Cas9. You were onto this at a very early point, and so you describe yourself just now as a foot soldier, anything but that, I see you as a veritable pioneer in this field. And there's another thing about you that I think is very special, and that is your ability to communicate this complex area and get it where everyone can understand it, which is all the more important as it gets rolled out to become a realistic alternative to these conditions that we've been talking about. So for that and so many things, I'm indebted to you. So Fyodor, what have I missed? We can't cover everything. You could write encyclopedias about this and it's changing every week. But have I missed anything that's important in the field of genome editing that you should close on?Fyodor Urnov (41:46):Well, so as far as your gracious words, now that I'm no longer blushing like a ripe tomato, I do want to honor the enormous group of people, my colleagues at Sangamo and in the academic community for building genome editing 1.0 and you among a very select few leaders in biomedicine who saw early the promise of gene editing. Again, I showcase our collaboration as an example of what true vision in biomedicine can do. I think I would imagine that your audience might say, what about CRISPR for enhancement? Well, I personally don't see anything wrong with well-informed adult human beings agreeing to being gene edited to enhance some feature of themselves once we know that it is safe and effective. But we are years, maybe a decade away from that. So if any of those listening receive an email from CRISPRmebeautiful.com, offering a gene editing enhancement service report, that email as vial spam!(43:21):CRISPR is amazing. It's affecting agriculture medicine in so many different ways and fundamental research, it's making an astonishing progress in the clinic. Medically speaking today, it is exactly where it needs to be as an experimental treatment for severe disorders, all of us have a dream where you can be crisp, you can sort of tune your genes, if you will. I don't know if I will live to see that, but for now, all of us have one prize in mind, which is make CRISPR available as a safe and effective medicine for severe existing disease. And we are working hard towards that, and I think we have a legitimate foundation for good hope.Eric Topol (44:13):Yeah, I think that's putting it very solid. It's probably now with the experience to date, not just in those hundreds of patients and in clinical trials, it continues to look extraordinary that it is going to fulfill the great, and as you said, it's not just in medicine. Many other walks of life are benefiting from this. And a lot of people don't realize that when you do a successful xenotransplant and you otherwise would die, but you give them a pig heart and you edit  50, 60 different genes in critical places so that it appears to the body as a human heart transplant, one that won't be rejected. Theoretically, you open up areas like that that are just so exceptional. But to also highlight that we're not talking, we're talking about somatic genome editing already, genes that are sick or need to be adjusted, if you will, not the ones in embryos that change the human race. No, we're not going there. The off target affects the safety. We'll learn more and more about this in the times ahead and the short times ahead with all the more people that are getting the first lines of treatment. So Fyodor, thank you so much. Thank you for your friendship over this extended period of time. You've taught me so much over the years, and I'm so glad we have a chance to regroup here, to kind of assess the field as it stands today and how it's going to keep evolving at a high velocity.Fyodor Urnov (45:58):My goodness, Eric, it's been amazing, amazing honor. And I should also say, and this is the truth, my morning ritual consists of two things, a shot of espresso, and seeing if you've posted anything interesting on Twitter, that is how I wake up my brain to take on the day. So thank you for not just your amazing vision and extraordinary efforts as a scientist and a physician scientist, but also thank you for the remarkable work you do in making critical advances in medicine and framing them in their exact right way for a very large audience. And I'm humbled and honored by your invitation to speak with you today in this setting. Let's just say that the moment this comes out, I'm going to tell my mom. Mom, yes. What? Oh my gosh. I have spoken with Eric Topol. She will be very excited.Eric Topol (46:53):Well, you're much too kind and we'll leave it there and reconvene in the future for a update because it won't be long before there'll be some substantial ones. Peter, thank you so much.Fyodor Urnov (47:05):Truly, truly a pleasure. Thank you.Thanks for listening (or reading, or both) this Ground Truths podcastPlease share if you found it informative! All proceeds from Ground Truths go to Scripps Research. Get full access to Ground Truths at erictopol.substack.com/subscribe

In which the Mister and I check out EL CONDE (2023), which is still streaming on Netflix.  From director Pablo Larraín, with a script from Pablo Larraín and Guillermo Calderón, the film follows Chilean dictator Augusto Pinochet, from his humble beginnings as a French soldier in the 18th century, to turning into a vampire, to fleeing during the French Revolution (with Marie Anotinette's head!) and then starting a new life in South America where he ultimately takes over after a coup.  Two hundred fifty years later and Augusto, also known as El Conde, is tired and has lost his will to live.  From there we're introduced to his family (wife and kids who are NOT vampires) and his loyal servant Fyodor, who is also a vampire.  And Carmen, the exorcism nun hired by one of his daughters who's been brought in to rid El Conde of the devil within him but is secretly there as an envoy of the Church to get to the hidden family wealth and bring it back to the Church.  The film has a run time of 1 h and 50 m and is rated R. Please note there are SPOILERS in this review. Opening intro music: GOAT by Wayne Jones, courtesy of YouTube Audio Library --- Support this podcast: https://podcasters.spotify.com/pod/show/jokagoge/support

This week we sit down with the captivatingly talented Fyodor Pavlov (artist talent behind his self-titled deck Fyodor Pavlov Tarot), to discuss his perspective on the creative process of making a Tarot Deck.  We discuss the upcoming Full Moon in Aries, as well as the Knights in Tarot. Creators we are loving this week are: @chloevegan's Two Dollar Series Unlocking the Secret Garden Oracle by US Games Listener Choice: Madeline Handcrafted

A network mapping tool that pings IP addresses looking for a response and can discover host names, open communications ports, operating system names and versions. Written and maintained by Gordon Lyon, a.k.a. Fyodor, it is a free and open source software application used by both system admins and hackers alike and has been a staple in the security community for well over two decades. CyberWire Glossary link: https://thecyberwire.com/glossary/nmap

A network mapping tool that pings IP addresses looking for a response and can discover host names, open communications ports, operating system names and versions. Written and maintained by Gordon Lyon, a.k.a. Fyodor, it is a free and open source software application used by both system admins and hackers alike and has been a staple in the security community for well over two decades. CyberWire Glossary link: https://thecyberwire.com/glossary/nmap Learn more about your ad choices. Visit megaphone.fm/adchoices

[English description below]Khởi điểm là một cửa hàng nhỏ ở vùng Syktyvkar, cực Bắc nước Nga với duy nhất một lò nướng, Dodo ở thời điểm hiện tại được xem là chuỗi pizza phát triển nhanh nhất thế giới.Tại tập podcast Vietnam Innovators tuần này, chúng ta sẽ cùng host Hảo Trần gặp gỡ Fyodor Ovchinnikov, Founder của Dodo Brands, người được mệnh danh là “Steve Jobs” của món pizza.Với hơn 900 cửa hàng trên khắp thế giới và tham vọng mở thêm 1000 cửa hàng trong 5 năm tiếp theo, có thể nói, thành công của chuỗi Dodo Pizza xoay quanh ba nguyên tắc cốt lõi: minh bạch, chất lượng đồng bộ nhờ công nghệ “đám mây” và sức mạnh cộng đồng trong việc gọi vốn.Còn điều gì thú vị đằng sau sự thành công rực rỡ của thương hiệu này? Cùng host Hảo Trần trò chuyện để tìm hiểu tại podcast này nhé.Xem phiên bản video trên YouTubeNếu có bất cứ góp ý, phản hồi hay mong muốn hợp tác, bạn có thể gửi email về địa chỉ team@vietcetera.com---From a small restaurant with only one oven in the basement of Syktyvkar in Russia's far north, Dodo has become the fastest-growing pizza chain in the world.On this week's Vietnam Innovators podcast, we will join host Hao Tran and Fyodor Ovchinnikov, the founder of Dodo Brands, who is dubbed the "Steve Jobs" of pizza.With over 900 stores worldwide and the ambition to open 1000 more stores in the next 5 years, the success of the Dodo Pizza chain revolves around three core principles. So what are they? What's the interesting story behind this brand's success?Let's chat with host Hao Tran to find out on this podcast.Listen to this episode on YouTube Feel free to leave any questions or invitations for business cooperation at team@vietcetera.com

In this episode we have some (now normal) lenghty banter and answer a listener's question about how they can get over a funk they've been in. Our deck of the episode is Esther twisting Holly's arm to FINALLY purchase the Fyodor Pavlov Tarot by Fyodor Pavlov!  Our book, The History of Tarot Art: Demystifying the Art and Arcana, Deck by Deck, is available now! Please leave an Amazon review to help with the algorithm! Do you love Holly and Esther, Existential Dread, and Bed? Then you'll love our face on everything! We got mugs, totes, phone cases, and even a tarot certification! You can find our merch here! Interact with us between episodes and join our Wildy Tarot Patreon , Facebook Group and Discord Server! You can follow us on Instagram, and while you're there you can also follow Holly and Esther.   

https://www.solgood.org - Check out our Streaming Service for our full collection of audiobooks, podcasts, short stories, & 10 hour sounds for sleep and relaxation at our websiteThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5114976/advertisement

Crime And PunishmentCrime And Punishment Full Book Introduction This is the story of Raskolnikov, an impoverished and lonely university student. To improve his family's living conditions and support himself, he robs and murders a selfish old woman. She is predatory and exploitative, amassing wealth and valuables as a loan shark. After the crime, he suffers excruciating remorse and inner torment. Raskolnikov becomes anxious and delirious. Finally, Sonia, a kindly and compassionate prostitute, inspires him to surrender to the authorities, and thus he experiences a tumultuous rebirth of the soul. Author : Fyodor DostoevskyFyodor Dostoevsky was a Russian realist writer born in 1821. He completed his first novel, Poor Folk, in 1845 and it received widespread acclaim. This early success paved the way for a brilliant literary career. His most renowned works include The Brothers Karamazov, Crime and Punishment, The Insulted and the Injured, The Idiot, and The House of the Dead. Dostoevsky's writings often focus on the inner dilemmas and suffering of underprivileged individuals from the lower strata of society. Dostoevsky uses in-depth psychological descriptions to create convincing character portraits. Overview | Chapter 1Hi, welcome to Bookey. Today we will unlock the novel Crime and Punishment. Fyodor Dostoevsky, the work's author, was a realist writer. Alongside Leo Tolstoy and Ivan Turgenev, he was one of the three towering figures of nineteenth-century Russian literature. Crime and Punishment is one of his most celebrated works and is widely acknowledged as a masterpiece. The novel explores social psychology as well as telling the story of crime and detection. It takes place in Saint Petersburg around the middle of the nineteenth century. The narrative concerns Raskolnikov, a university law student. After committing a murder, he is wracked by inner torment. Finally, he experiences a spiritual rebirth, but not until he has been inspired to turn himself in by Sonia, a kindly Christian soul. In the book, Dostoevsky masterfully details the psychological changes that occur after the murderer commits their crime. In 1864, Fyodor Dostoevsky, with his brother Mikhail founded the literary magazine Epokha. The magazine published Fyodor's and other authors' works. After the death in the same year of both Fyodor's first wife, Maria, and Mikhail, Dostoevsky fell into financial difficulty, running up huge debts with his creditors. It forced him to stop publishing the magazine and commit to an unfair contract with another publisher for his work. However, this unfavorable agreement led to the completion of this novel, Crime and Punishment. Many of Dostoevsky's writings are introspective and discreet. His dissection of the human psyche is simultaneously comprehensive and profound, barbed and unforgiving, expansive and detailed. The Austrian writer Franz Kafka once said, “A book must be the axe for the frozen sea within us.” Dostoevsky's works can be considered as such axes. If Tolstoy has shown us the breadth of Russian literature, then it can be said that Dostoevsky represents its depth. Through his writings, Dostoevsky, having himself experienced life's hardships, attempts to expose society's darkness and criminality. He describes the living conditions and sufferings of the underprivileged and expresses his heartfelt sympathy for their plight. He articulates the need for social change. As the Russian poet Merezhkovsky once said, Dostoevsky is sometimes closer to us than our loved ones. In sickness, he is a fellow patient. In both good and evil deeds, he is an accomplice. Nothing brings people...

Imagine war becoming your new normal. Imagine getting used to things like airstrike sirens. Imagine sleeping through the distant bombs. Imagine passing through the rubble on your way to work, or school, or church.Over the past year, war has become the new normal for Ukrainian pastor and theologian Fyodor Raychynets. Most of the expectations for how tthis war might go have fallen through. Worst case scenarios have come to pass. And the precarity and fragility of life outside of wartime—well, that continues too.A year ago, 20 days into the war, Fyodor joined Miroslav Volf to catch up with his former professor for a conversation on the immediate impact of Russia's invasion on Ukrainian life and culture. At the time, uncertainty filled the globe. Now, after 387 days of war, the shock has numbed into weariness. But a consistent message of presence pervades Fyodor's mindset. Providing humanitarian aide, friendship, and surrogate family in the wake of so much destruction and loss, his church in the outskirts of Kiev has grown.In this episode, Ukrainian pastor and theologian Fyodor Raychynets provides an update on life during wartime, in a war zone—which includes not only the pain of war, but the grief of losing his wife prior to the war, and his adult son just months ago. His faith persists in the face of all the cold reminders of how little control any of us exert on world events such as this. He now turns to the minor prophets—Nahum and Habakkuk in particular—to hope for justice, to complain and express his anger toward God, even with God. And he continues to minister to soldiers and civilians, holding their questions with presence and patience, while preaching a message of hope in the good and resistance to evil.Thanks for listening friends, even on this 387th day of war in Ukraine.About Fyodor RaychynetsFyodor Raychynets is a theologian and pastor in Kyiv, Ukraine. He is Head of the Department of Theology at Ukrainian Evangelical Theological Seminary, where he teaches courses in Leadership and Biblical Studies, particularly the Gospel of Matthew. He studied with Miroslav Volf at Evangelical Theological Seminary in Osijek, Croatia.Follow him on Facebook here.Production NotesThis podcast featured theologians Fyodor Raychynets and Miroslav VolfEdited and Produced by Evan RosaHosted by Evan RosaProduction Assistance by Macie Bridge & Kaylen YunA Production of the Yale Center for Faith & Culture at Yale Divinity School https://faith.yale.edu/aboutSupport For the Life of the World podcast by giving to the Yale Center for Faith & Culture: https://faith.yale.edu/give

Steven DeLay earned his PhD in philosophy at Oxford in 2017 and is the author of several books of philosophy and fiction, including a handful now with Wipf and Stock. In this standalone interview, Steven talks Kierkegaard, phenomenology, philosophy for Protestants, and the relationship between theology and fiction. PODCAST LINKS: Blog post: https://wipfandstock.com/blog/2023/02/07/standalone-episode-steven-delay-kierkegaard-phenomenology-and-the-relationship-between-philosophy-and-theology-and-fiction/ Steven's author page: https://wipfandstock.com/author/steven-delay/ Steven's website: https://stevendelay.com/ Steven's academia.edu page: https://oxford.academia.edu/StevenDeLay Temple Coffee Roasters: https://templecoffee.com/ CONNECT: Website: https://wipfandstock.com/ Twitter: https://twitter.com/wipfandstock Facebook: https://www.facebook.com/wipfandstock Instagram: https://www.instagram.com/wipfandstock/ YouTube: https://www.youtube.com/channel/UCvht9V0Pndgvwh5vkpe0GGw SOURCES MENTIONED: Bergo, Bettina. Anxiety: A Philosophical History. Chrétien, Jean-Louis. Conscience et roman 1: La conscience au grand jour. Clemente, Matthew. “As If It Were True: An Interview with Richard Kearney.” DeLay, Steven. In the Spirit: A Phenomenology of Faith. ———. Phenomenology in France: A Philosophical and Theological Introduction. Dostoevsky, Fyodor. Crime and Punishment. Falque, Emmanuel. Crossing the Rubicon: The Borderlands of Philosophy and Theology. Fowles, John. The Magus: A Novel. Graves, Adam J. The Phenomenology of Revelation in Heidegger, Marion, and Ricoeur. Heidegger, Martin. Being and Time. Hopp, Walter. Phenomenology: A Contemporary Introduction. Kierkegaard, Soren. Fear and Trembling. Marion, Jean-Luc. Being Given: Toward a Phenomenology of Givenness. ———. A Brief Apology for a Catholic Moment. ———. God Without Being: Hors-Texte. ———. The Idol and Distance: Five Studies. ———. Negative Certainties. ———. Reduction and Givenness: Investigations of Husserl, Heidegger, and Phenomenology. Pascal, Blaise. Pensées. Plantinga, Alvin. Warranted Christian Belief. Rudd, Anthony. Painting and Presence: Why Paintings Matter. Sellars, Wilfrid. Empiricism and the Philosophy of Mind. OUTLINE: (01:28) – Decaf coffee, black coffee (04:14) – Favorite books of 2022 (07:09) – Rice University – Oxford University (09:43) – A conversion via Kierkegaard (12:35) – Literature – philosophy – phenomenology – theology (16:52) – Barth, Bultmann, and Rudolf Otto (18:46) – Why should Christians read philosophy? (23:05) – The merits of reading atheists and agnostics (29:13) – Heidegger, onto-theology, and negative theology (32:45) – Phenomenology a Catholic science? (39:38) – Philosophy for Protestants (41:30) – The GOAT of phenomenology (44:16) – The hermeneutical critique of phenomenology (47:41) – Desert island: phenomenology books (49:38) – Philosophy and fiction (59:31) – Steven's forthcoming work

After three weeks of discussing the logical problem of Evil, this episode will cover a few listener comments on the subject. One commenter, as if through their own seer stone, knew where Scott would take this subject four weeks in advance. The Brothers Karamazov offers a fascinating conclusion to the discussion. This book by Fyodor… Read More »Rameumptom Ruminations: 084: Is God Worthy of my Worship? The post Rameumptom Ruminations: 084: Is God Worthy of my Worship? appeared first on Mormon Discussions Podcasts - Full Lineup.

After three weeks of discussing the logical problem of Evil, this episode will cover a few listener comments on the subject. One commenter, as if through their own seer stone, knew where Scott would take this subject four weeks in advance. The Brothers Karamazov offers a fascinating conclusion to the discussion. This book by Fyodor… Read More »Rameumptom Ruminations: 084: Is God Worthy of my Worship?

The Luminaries series is a collection of interviews with premier thinkers working in the theological academy and the church. Fr. John Behr is the Regius Professor of Humanity at the University of Aberdeen and an esteemed scholar of the patristics, having published several translations of various Church Fathers and monographs of his own on patristic figures and patristic theology. Here we discuss the Gospel of John, Irenaeus and Origen, and the mystery of Christ and of life in death. PODCAST LINKS: Blog post: https://wipfandstock.com/blog/2023/01/10/luminaries-john-behr-the-gospel-of-john-irenaeus-and-origen-and-the-mystery-of-life-in-death/ Fr. Behr's website: https://frjohnbehr.com/ CONNECT: Website: https://wipfandstock.com/ YouTube: https://www.youtube.com/channel/UCvht9V0Pndgvwh5vkpe0GGw Twitter: https://twitter.com/wipfandstock Facebook: https://www.facebook.com/wipfandstock Instagram: https://www.instagram.com/wipfandstock/ SOURCES MENTIONED: Ashton, John. Understanding the Fourth Gospel. Athanasius. On the Incarnation. Behr, John. Asceticism and Anthropology in Irenaeus and Clement. ———. Irenaeus of Lyons: Identifying Christianity. ———. John the Theologian and his Paschal Gospel: A Prologue to Theology. ———. The Nicene Faith. Formation of Christian Theology 2. ———. The Way to Nicaea. Formation of Christian Theology 1. ———, and Conor Cunningham, eds. The Role of Death in Life: A Multidisciplinary Examination of the Relationship between Life and Death. Brown, Peter. The Body and Society: Men, Women, and Sexual Renunciation in Early Christianity. Derrida, Jacques. The Gift of Death. Dostoevsky, Fyodor. The Possessed. Foucault, Michel. The History of Sexuality. 3 vols. Henry, Michel. I Am the Truth: Toward a Philosophy of Christianity. ———. Incarnation: A Philosophy of the Flesh. ———. Words of Christ. Käsemann, Ernst. The Testament of Jesus: A Study of the Gospel of John in the Light of Chapter 17. Origen. On First Principles. Translated by John Behr. Sanders, E. P. Paul and Palestinian Judaism: A Comparison of Patterns of Religion. OUTLINE: (01:31) – Diner coffee and assam/lapsang souchong tea (02:31) – John the Theologian (09:01) – Rediscovering modern philosophy (10:42) – The Prologue to the Gospel of John (18:11) – “And the Word was towards God” (27:07) – Contemporary scholarship on Irenaeus (30:43) – The “Great Church” and heresy (37:30) – The body: Church fathers, Peter Brown, Foucault (41:33) – Origen in translation (52:11) – Death: re-thinking “it is finished” (01:04:53) – What's wrong with “the Bible” (01:11:43) – Original sin and the Fall

Many Europeans see the war in Ukraine as an attack on the ‘rules-based order'. But to many people in other parts of the world, there is no consensus on a set of rules to govern global affairs – and no sense of order. In this mini-series, Mark Leonard will go on an intellectual tour of the world, talking to key thinkers about how order is being defined by different powers. He explores how the clash between these different notions plays into the big shocks facing the world – from climate change and future pandemics to geopolitical struggles and technological disasters – and what this means for national and global politics. --- In this fourth instalment, Leonard is joined by Fyodor Lukyanov – chair of the Council on Foreign and Defense Policy and editor-in-chief of the Russia in Global Affairs journal – to learn more about the Russian perspective on global order. Why is the Kremlin so keen on regional integration? How can power guarantee freedom and achieve justice in a rules-based order? And finally, what role do the Soviet Union and notions of imperial greatness play in Vladimir Putin's ideal of Russia? Bookshelf: • Russia in Global Affairs journal, Issue 3 2022 July/September and Issue 4 2022 October/November • “Europe, Russia and the Liberal World Order: International Relations after the Cold War” by Timofei Bordachev • Complete works of Nikolai Gogol

View our full collection of podcasts at our website: https://www.solgoodmedia.com or YouTube channel: www.solgood.org/subscribe

Interview LinksCheck out Nmap if, for some reason, you haven't already.Learn about Npcap, the packet capture library tool that Gordon and his company also offer.Watch Gordon and HD Moore, the creator of Metasploit, chat about the evolution of network scanning on YouTube.Rapid Rundown LinksRead the Bleeping Computer story on hackers using DeFi bugs to steal cryptocurrency.Like the show? Want to keep Jen and Tod in the podcasting business? Feel free to rate and review with your favorite podcast purveyor, like Apple Podcasts.

В этом подкасте Настя рассказывает об известном классике русской литературы Фёдоре Михайловиче Достоевском.

Ukrainian pastor and theologian Fyodor Raychynets talks about living out your faith in God in the midst of the current war with Russia.   Show notes: Interview with Fyodor by Baptist News Global  Podcast Episode with Miroslav Volf Interviewing Fyodor  Like what you hear? Leave a tip. Join the mailing list churchandmain.org Leave a Review: https://ratethispodcast.com/churchandmain Email: hello@enroutepodcast.org

Tsar Alexei is dead, long live Tsar Fyodor - except..... he's ill, Russia is fighting the Ottomans and the Romanovs are divided.   Period Covered 1676 - 1682   Website   https://www.historyofrussia.net Twitter       HistoryRussia1 Email        nordicworld@outlook.com

Today on the Ether we have the Anchor Protocol semi dynamic earn rate AMA hosted by Danku with bitN8, Fyodor, Capricious Sage, Ryan Park, and more! Recorded on April 28th 2022. Make sure to check out our current sponsor Orbital Command! We appreciate their support. You can check out all the sponsors that have supported TerraSpaces here on our Sponsors Page.

Today on the Ether we have the Anchor Protocol AMA with Risk Harbor and the Wharton School. You'll hear from bitN8, Fyodor, Max Resnick, Nena Fizz, J, and more! Recorded on April 21st 2022. Make sure to check out our sponsors, Orbital Command and Talis! We appreciate their support.

Today on the Ether we have the Phezzan Protocol X Anchor Protocol AMA hosted by Danku. You'll hear from Cephii, bitN8, Fyodor, and more! Recorded on April 13th 2022. Make sure to check out our sponsors, Orbital Command, Luart, Talis, and Intern Capital! We appreciate their support.

Today on the Ether we have the Anchor Protocol bATOM AMA hosted by Danku with special guests pSTAKE. You'll be hearing from Mikhil Pandey, Fyodor, Nena Fizz, Abhitej Singh, bitN8, and more! Recorded on March 31st 2022. Make sure to check out our sponsors, Orbital Command, Luart, Talis, and Glow Yield! We appreciate their support.

Psychedelic philosophy without the ordinary substances. Part talk, part improv audience participation. Filmed on March 13 2022 at Esoteric Transformational Festival in Victoria, Australia. Support this channel @ www.patreon.com/voicecraft Learn more through the show notes @ www.voicecraft.io/e63-psychedelic-philosophy-talk-at-esoteric-festival --- Thank you to Fyodor, Evan, and Cameron Duffy for stepping up to join me.

Today on the Ether we have the Anchor Protocol dynamic earn rate prop discussion hosted by Orbital Command with Danku, Retrograde, Pong, Fyodor, and bitN8. Recorded on March 23rd 2022. Make sure to check out our sponsors, Orbital Command, Luart, Talis, WeFund, and Glow Yield! We appreciate their support.

Today we're sharing a conversation between Miroslav Volf and Fyodor Raychynets, a former student of Miroslav's when he taught at Evangelical Theological Seminary in Osijek, Croatia in the early '90s. Fyodor is a theologian and pastor in Kyiv, and is head of the department of theology at Ukrainian Evangelical Theological Seminary on the northwest outskirts of the city, 20 kilometers outside downtown Kyiv.We spoke to Fyodor on Sunday, March 13, 2022, just as he came in for the 8pm curfew after a day of feeding the elderly, the sick, weary soldiers, and women and children stuck in the basements without electricity, without clean water, without medication, and increasingly, without a clear idea of how any of this will end for them. That day Fyodor visited his seminary campus to find it had been shelled by three missiles, destroying much of the campus, including his office, leaving his library of books destroyed.In this conversation, Fyodor shares his experience, now after 20 days of war, 20 days of being under siege, and 20 days of prayer and feeding the hungry.Fyodor posts daily updates and reflections on his Facebook page, you can find a link in the show notes. Each daily post begins with developments in the war and how it's impacting him, his team of fellow ministers, and the city around him. He then reflects on the nature of war itself, and its impact on human life. He closes each post with a prayer for Ukraine, for freedom, for humanity. I'll quote just a few of his moving passages.Day 7, "War is when the safest place to sleep in your apartment is the bathroom, although that's obviously for other purposes.."Day 11, "War is when the most vulnerable suffer. That's when ordinary things, for example, going to the store and buying fresh, warm and fragrant Ukrainian bread (I've visited about 70 countries, but I've never eaten such delicious bread) become impossible. It's when you meet people every day who haven't eaten bread for 4 or 5 days, not to mention anything else...."Day 15, "War is when evil reaches unseen dimensions and lowest forms, and when good manifests itself in its highest manifestations against the backdrop of total uncontrollable madness."Day 19, "War is when you wake up in the morning, if you managed to fall asleep at all, not from the alarm clock or birds singing, but to the sounds of sirens, or bomb explosions that make you tremble. War is when your emotional state shifts from optimistic to pessimistic more often than in peaceful time, and the emotional range itself is much wider."Day 20, written just a few hours ago. "War is when your understanding changes when not in theory but in practice you especially appreciate the moment "here and now" and live it more consciously..."About Fyodor RaychynetsFyodor Raychynets is a theologian and pastor in Kyiv, Ukraine. He is Head of the Department of Theology at Ukrainian Evangelical Theological Seminary, where he teaches courses in Leadership and Biblical Studies, particularly the Gospel of Matthew. He studied with Miroslav Volf at Evangelical Theological Seminary in Osijek, Croatia. Follow him on Facebook here.Production NotesThis podcast featured theologians Fyodor Raychynets and Miroslav VolfEdited and Produced by Evan RosaHosted by Evan RosaA Production of the Yale Center for Faith & Culture at Yale Divinity School https://faith.yale.edu/aboutSupport For the Life of the World podcast by giving to the Yale Center for Faith & Culture: https://faith.yale.edu/give

Today on the Ether we have the veANC AMA hosted by Danku with José Maria Macedo, bitN8, Fyodor, and of course, Retrograde Money, Atari, Pong, and more! Recorded on March 10th 2022. Make sure to check out our sponsors, Orbital Command, Luart, Talis, WeFund, and Glow Yield! We appreciate their support.

Today on the Ether we have the tokenomics discussion hosted by Anchor Protocol and Danku_r with Fyodor, bitN8, José Maria Macedo, Retrograde, Atari, Tetris, Pong, and more! Recorded on February 24th 2022. Make sure to check out our sponsors, Orbital Command, Luart, Talis, and WeFund! We appreciate their support.

Thursday's episode of Locked On Blackhawks begins with an update from The Athletic suggesting that the Chicago Blackhawks might be the front-runner for Blue Jackets' defenseman Seth Jones. Then, host Jack Bushman takes a deeper look at Russian forward Fyodor Svechkov's 2021 NHL Draft Profile. The episode concludes with forward Ryan Carpenter's 2021 Season Recap. All that and more on Locked On Blackhawks. Part of the Locked On Podcast Network. Your Team. Every Day.Amazing selection. Reliably low prices. All the parts your car will ever need. Visit RockAuto.com and tell them Locked On sent you.There is only 1 place that has you covered and 1 place we trust. Betonline.ag! Sign up today for a free account at betonline.ag and use that promocode: LOCKEDON for your 50% welcome bonus.Seth Jones Latest (1:40)Fyodor Svechkov's Draft Profile (8:20)Ryan Carpenter's Season Recap (17:05) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Kyle, Erik, and JD are joined by Dylan Griffing of EP Rinkside to discuss the best defensive forward in the class, Fyodor Svechkov. We look at his statistical profile, and if the San Jose Sharks were to move down, how he could help solidify the bottom-six (9:30), and where Svechkov could land (12;30). We finish by talking about bigger draft trends (17:30) and our blood pact questions (20:00).Check out the podcast on Twitter, Instagram, and Facebook.Support Us By Supporting Our Sponsors!BetOnline AGThere is only 1 place that has you covered and 1 place we trust. Betonline.ag! Sign up today for a free account at betonline.ag and use that promocode: LOCKEDON for your 50% welcome bonus.Built BarBuilt Bar is a protein bar that tastes like a candy bar. Go to builtbar.com and use promo code “LOCKED15,” and you'll get 15% off your next order.Rock AutoAmazing selection. Reliably low prices. All the parts your car will ever need. Visit RockAuto.com and tell them Locked On sent you. Learn more about your ad choices. Visit podcastchoices.com/adchoices

#DraftSZN rolls on at Locked On Red Wings with a pair of profiles on Russian forwards Nikita Chibrikov and Fyodor Svechkov. We're joined by Elite Prospects' Dylan Griffing to get a full scope of each player's game, where the best place would be for the Red Wings to draft them, what the timeline to the NHL looks like, projectability, and a whole lot more.Support Us By Supporting Our Sponsors!BetOnline AGThere is only 1 place that has you covered and 1 place we trust. Betonline.ag! Sign up today for a free account at betonline.ag and use that promocode: LOCKEDON for your 50% welcome bonus.Built BarBuilt Bar is a protein bar that tastes like a candy bar. Go to builtbar.com and use promo code “LOCKED15,” and you'll get 15% off your next order.Rock AutoAmazing selection. Reliably low prices. All the parts your car will ever need. Visit RockAuto.com and tell them Locked On sent you.WealthfrontTo get your first $5,000 managed for FREE, for life, go to wealthfront.com/LockedOnNHL.StatHeroStatHero, the FIRST Ever Daily Fantasy Sportsbook that gives the PLAYER the ADVANTAGE. Go to StatHero.com/LockedOn for 300% back on your first play. Lucy.CoGo to Lucy.co and use Promo Code LOCKEDONNHL to get20% off all products on your first order, including gum or lozenges.  Learn more about your ad choices. Visit podcastchoices.com/adchoices